var title_f25_38_26208="Measurement levator function";
var content_f25_38_26208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Measurement of levator function of the upper lid with the patient in downgaze (left) and upgaze (right)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The brow should be better fixated to prevent frontalis action on the eyelid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26208=[""].join("\n");
var outline_f25_38_26208=null;
var title_f25_38_26209="Postterm pregnancy";
var content_f25_38_26209=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Postterm pregnancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/38/26209/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26209/contributors\" id=\"au4939\">",
"       Errol R Norwitz, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/38/26209/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26209/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/38/26209/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26209/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/38/26209?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Although pregnancy is said to last nine months, healthcare providers track pregnancy by weeks and days. The normal duration of pregnancy is approximately 37 to 42 weeks, with the estimated due date at 40 weeks or 280 days from the first day of the last menstrual period.",
"    </p>",
"    <p>",
"     A postterm pregnancy, also called a prolonged pregnancy, is one that has extended beyond 42 weeks from the first day of the last menstrual period. As many as 10 percent of pregnancies are postterm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Accurate dating",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is essential to ensure that the pregnancy is in fact postterm. Ideally, an accurate gestational age is determined early in the pregnancy. In women who have regular menstrual periods, the date can often be reliably calculated based on the last period.",
"    </p>",
"    <p>",
"     If there is uncertainty about the dates, or if the size of the woman's uterus is larger or smaller than expected based on the date of the last period, the gestational age of the fetus and due date can be estimated based upon findings on fetal ultrasound examination. This estimate is most accurate when performed early in pregnancy; ultrasounds performed in the last half of pregnancy are less reliable for estimating the due date.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      POSTTERM PREGNANCY CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     In most cases, the cause of postterm pregnancy is unknown. There are some factors that place a woman at increased risk. The incidence is higher in first pregnancies and in women who have had a previous postterm pregnancy. Genetic factors may also play a role. One study showed an increased risk of postterm pregnancy in women who were, themselves, born postterm.",
"    </p>",
"    <p>",
"     However, variations in when a woman ovulates can lead to errors in calculating the true duration of pregnancy and lead to over- and underestimations of when the baby is due. An ultrasound examination performed in the first one-half of pregnancy is the most reliable method of calculating the date the baby is due, especially in women with long or irregular menstrual cycles.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      POSTTERM PREGNANCY RISKS",
"     </span>",
"    </p>",
"    <p>",
"     Pregnancy that continues beyond 42 weeks is associated with risks to the fetus and the mother.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Risks to the fetus",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Stillbirth or neonatal death",
"     </span>",
"     &nbsp;&mdash;&nbsp;The incidence of stillbirth or infant death is increased in pregnancies that continue beyond 42 weeks. However, the risk is relatively small, with only 4 to 7 deaths per 1000 deliveries. By comparison, the risk of stillbirth or infant death in pregnancies between 37 and 42 weeks is 2 to 3 per 1000 deliveries.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Large body size",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postterm fetuses have a greater chance of developing complications related to larger body size (called macrosomia), which is defined as weighing more than 4500 grams, or about 10 pounds. Complications can include prolonged labor, difficulty passing through the vagina, and birth trauma (eg, fractured bones or nerve injury) related to difficulty in delivering the shoulders (shoulder dystocia).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Fetal dysmaturity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Also called \"postmaturity syndrome,\" this refers to a fetus whose growth in the uterus after the due date has been restricted, usually due to a problem with delivery of blood to the fetus through the placenta.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Meconium aspiration",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond term, the fetus is more likely to have a bowel movement, called meconium, into the amniotic fluid. If the fetus is stressed, there is a chance it will inhale some of this meconium stained amniotic fluid; this can cause breathing problems when the baby is born.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Risks to the mother",
"     </span>",
"     &nbsp;&mdash;&nbsp;Risks to the mother are related to the larger size of postterm infants, and include difficulties during labor, an increase in injury to the perineum (including the vagina, labia, and rectum), and an increased rate of cesarean birth with its associated risks of bleeding, infection, and injury to surrounding organs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      POSTTERM PREGNANCY TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Antenatal fetal monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, a healthcare provider will recommend tests on the fetus if the pregnancy extends beyond the due date. These tests give information about the health of the fetus and about the risks or benefits of allowing the pregnancy to continue.",
"    </p>",
"    <p>",
"     The American College of Obstetricians and Gynecologists has stated that it is only necessary to start antenatal fetal monitoring after 42 weeks (294 days) of gestation, although many obstetric care providers will start fetal testing at 41 weeks. Many experts recommend twice weekly testing, including a measurement of amniotic fluid volume. Testing may include observing the fetus' heart rate using a fetal monitor (called a nonstress test) or observing the baby's activity with ultrasound (called a biophysical profile).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Nonstress testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonstress testing is done by monitoring the baby's heart rate with a small device that is placed on the mother's abdomen. The device uses sound waves (ultrasound) to measure the baby's heart rate over time, usually for 20 to 30 minutes. Normally, the baby's baseline heart rate should be between 110 and 160 beats per minute and should increase above its baseline by at least 15 beats per minute for 15 seconds when the baby moves.",
"    </p>",
"    <p>",
"     The test is considered reassuring (called \"reactive\") if two or more fetal heart rate increases are seen within a 20 minute period. Further testing may be needed if these increases are not observed after monitoring for 40 minutes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Biophysical profile",
"     </span>",
"     &nbsp;&mdash;&nbsp;A biophysical profile (BPP) score is calculated to assess the fetus' health. It consists of five components, nonstress testing and ultrasound measurement of four fetal parameters: fetal body movements, breathing movements, fetal tone (flexion and extension of an arm, leg, or the spine), and amniotic fluid volume. Each component is scored individually, 2 points if normal and 0 points if not normal. The maximum possible score is 10.",
"    </p>",
"    <p>",
"     Amniotic fluid volume is an important variable in the BPP because a low volume (called oligohydramnios) may increase the risk of umbilical cord compression and may be a sign of changes in the feto-uteroplacental circulation. Amniotic fluid level can become reduced within a short time period, even a few days.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Contraction stress test",
"     </span>",
"     &nbsp;&mdash;&nbsp;A contraction stress test (CST) can also be done to assess fetal health. It involves giving an intravenous medication (oxytocin) to the mother to induce uterine contractions. The fetus' heart rate is monitored in response to the contractions. A fetus whose heart rate slows down during a CST may require a cesarean delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Inducing labor",
"     </span>",
"     &nbsp;&mdash;&nbsp;The optimal time to deliver a baby in a woman who is postterm is sometimes hard to determine. The healthcare provider and woman must consider the risks and benefits of continuing the pregnancy, the results of antenatal testing, and the condition of the cervix (the lower part of the uterus, which opens into the vagina). Normally, the cervix begins to dilate (open) and efface (thin) towards the end of a woman's pregnancy. Inducing labor is more likely to fail in women whose cervix is not dilated or thinned (called ripe), which could require the woman to undergo cesarean birth.",
"    </p>",
"    <p>",
"     Most healthcare providers will induce labor if it does not begin spontaneously by 41 to 42 weeks of gestation. For a woman whose cervix is not ripe, labor can be induced with a medication applied directly to the cervix or in the vagina, which causes the cervix to ripen. Cervical ripening may also be accomplished using mechanical methods such as a Foley catheter bulb. Most women, including those whose cervix is ripe, will also require an intravenous medication, oxytocin, which stimulates the uterus to contract; uterine contractions further stimulate cervical dilation and effacement. If induction of labor does not completely dilate and efface the cervix, or if complications develop that require the baby to be delivered quickly, a cesarean delivery is usually performed.",
"    </p>",
"    <p>",
"     Some patients may choose to have a cesarean delivery, especially if the fetus is macrosomic (defined as an estimated fetal weight of greater than or equal to 4500 grams [about 10 pounds]), they have a history of previous cesarean delivery, or for reasons of personal choice. It is important to understand the risks and benefits of cesarean delivery, and to discuss these issues with the physician who will be performing the procedure. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      POSTTERM INFANTS",
"     </span>",
"    </p>",
"    <p>",
"     Some postterm infants have a distinctive appearance. The arms and legs may be long and thin. The skin may appear dry and parchment-like, with peeling and sometimes meconium staining. The skin may appear loose, especially over the thighs and buttocks. Scalp hair may be longer or thicker, and the fingernails and toenails may be long. Postterm newborns are typically very alert, and may have a \"wide-eyed\" look.",
"    </p>",
"    <p>",
"     Few studies have examined long-term outcomes (eg, growth and development patterns, intelligence) of postterm infants. In general, the outcome appears similar in both postterm and term infants.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A postterm pregnancy is one that extends beyond 42 weeks from the first day of the last menstrual period; as many as 10 percent of pregnancies are postterm.",
"      </li>",
"      <li>",
"       The chance of postterm pregnancy is higher in first pregnancies and in women who have had a postterm pregnancy in the past. Genetic factors may play a role. (See",
"       <a class=\"local\" href=\"#H3\">",
"        'Postterm pregnancy causes'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       There are certain risks associated with postterm pregnancy. The chance of stillbirth or infant death increases slightly, and the fetus may develop problems due to having restricted space in the uterus or inhaling meconium (bowel movement). The increased size of the fetus can lead to complications, some of which can affect the mother during delivery. (See",
"       <a class=\"local\" href=\"#H4\">",
"        'Postterm pregnancy risks'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Tests are used to monitor the health of a postterm fetus and the safety of allowing the pregnancy to continue. (See",
"       <a class=\"local\" href=\"#H12\">",
"        'Antenatal fetal monitoring'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       For most women, labor is induced if it has not occurred by 41 to 42 weeks. Some women will elect to have a cesarean delivery if the fetus has grown to a very large size. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Inducing labor'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Some postterm infants have a distinctive appearance, with long and thin arms, dry and sometimes loose-appearing skin, and longer hair and nails. Postterm infants tend to be very alert at birth. (See",
"       <a class=\"local\" href=\"#H17\">",
"        'Postterm infants'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498669300\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12644747\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/33/15890?source=see_link\">",
"      Patient information: When your baby is overdue (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/2/19490?source=see_link\">",
"      Patient information: Shoulder dystocia (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12644756\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"      Oligohydramnios",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=see_link\">",
"      Postterm pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/38/26209/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/38/26209?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26209/abstract/1\">",
"      Rosen MG, Dickinson JC. Management of post-term pregnancy. N Engl J Med 1992; 326:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26209/abstract/2\">",
"      Rand L, Robinson JN, Economy KE, Norwitz ER. Post-term induction of labor revisited. Obstet Gynecol 2000; 96:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26209/abstract/3\">",
"      Alfirevic Z, Walkinshaw SA. Management of post-term pregnancy: to induce or not? Br J Hosp Med 1994; 52:218.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_38_26209=[""].join("\n");
var outline_f25_38_26209=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           POSTTERM PREGNANCY CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           POSTTERM PREGNANCY RISKS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           POSTTERM PREGNANCY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           POSTTERM INFANTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_38_26210="Rigid plastic suction curette";
var content_f25_38_26210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigid plastic uterine suction curette",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonflexible curved #10 suction curette (10-mm diameter) used for evacuation of uterine contents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26210=[""].join("\n");
var outline_f25_38_26210=null;
var title_f25_38_26211="Clamping cardinal ligaments";
var content_f25_38_26211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clamping and suture ligation of the cardinal ligaments during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26211=[""].join("\n");
var outline_f25_38_26211=null;
var title_f25_38_26212="Transabdominal CVS";
var content_f25_38_26212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Technique for transabdominal chorionic villus sampling (CVS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the transabdominal CVS technique, the physician guides a needle from the patient's abdomen into the placenta under ultrasound guidance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26212=[""].join("\n");
var outline_f25_38_26212=null;
var title_f25_38_26213="Pemphigus vulgaris oral lesions";
var content_f25_38_26213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions on the tongue and lips are present in this patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26213=[""].join("\n");
var outline_f25_38_26213=null;
var title_f25_38_26214="Pilar cyst 3";
var content_f25_38_26214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pilar cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26214=[""].join("\n");
var outline_f25_38_26214=null;
var title_f25_38_26215="Zolpidem: Pediatric drug information";
var content_f25_38_26215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zolpidem: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"    see \"Zolpidem: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/44/21189?source=see_link\">",
"    see \"Zolpidem: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15898498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Recommending Lower Initial Zolpidem Doses to Reduce Risk of Morning Somnolence",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is requiring manufacturers of zolpidem products (Ambien&reg;, Ambien CR&reg;, Edluar&trade;, and Zolpimist&reg;) to change labeling to recommend lower starting doses of zolpidem in women. Blood levels in women may remain high enough the morning after use to impair activities that require alertness, including driving. Women appear to be more sensitive to this effect because they eliminate zolpidem more slowly than men, although the FDA is also recommending that the lower doses be considered for men. The recommendation is focused on zolpidem products approved for use immediately before bedtime. The FDA is recommending that the doses for immediate-release products be lowered from 10 mg to 5 mg and from 12.5 mg to 6.25 mg for extended-release products in women.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Patients already prescribed zolpidem should contact their healthcare provider prior to adjusting their dose.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information can be found at",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334798.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334798.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F236158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambien CR&reg;;",
"     </li>",
"     <li>",
"      Ambien&reg;;",
"     </li>",
"     <li>",
"      Edluar&trade;;",
"     </li>",
"     <li>",
"      Intermezzo&reg;;",
"     </li>",
"     <li>",
"      Zolpimist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13452765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sublinox&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1043344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic, Nonbenzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1043377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"      see \"Zolpidem: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: Limited data available; efficacy results variable and have",
"     <b>",
"      not",
"     </b>",
"     been demonstrated in randomized placebo-controlled trials. An open-label, dose escalation pharmacokinetic evaluation showed zolpidem was well-tolerated in pediatric patients 2-18 years of age and recommended a dose of 0.25 mg/kg at bedtime for evaluation in future efficacy trials (Blumer, 2008). A single case report describes an 18-month-old infant who was effectively treated with zolpidem for primary insomnia (Bhat, 2008). However, zolpidem has",
"     <b>",
"      not",
"     </b>",
"     been shown to be effective in a randomized placebo-controlled trial (n=201) of children aged 6-17 years with ADHD-associated insomnia; zolpidem 0.25 mg/kg/dose (maximum dose: 10 mg) administered nightly did",
"     <b>",
"      not",
"     </b>",
"     decrease sleep latency; in addition, hallucinations occurred in 7.4% of patients (Blumer, 2009). A comparative, randomized controlled trial of zolpidem and haloperidol in pediatric burn patients (n=40, mean age: 9.4 &plusmn; 0.7 years) showed zolpidem dosed at 0.5 mg/kg nightly for one week (maximum dose: 20 mg) minimally increased Stage 3/4 sleep and REM but not total sleep time; the authors no longer use zolpidem to try to improve sleep in their pediatric burn patients (Armour, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release tablet, spray: 10 mg immediately before bedtime; maximum dose: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release tablet: 12.5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sublingual tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Edluar&trade;: 10 mg immediately before bedtime; maximum dose: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermezzo&reg;:",
"     <b>",
"      Note:",
"     </b>",
"     Take only if &ge;4 hours left before waking",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Females: 1.75 mg once per night as needed (maximum: 1.75 mg/night)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Males: 3.5 mg once per night as needed (maximum: 3.5 mg/night)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Dosage  adjustment with concomitant CNS depressants: Females and males: 1.75 mg once per night as needed; dose adjustment of concomitant CNS depressant(s) may be necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"     Adults: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, some zolpidem labeling recommends monitoring patients with renal impairment closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release tablet, spray: 5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release tablet: 6.25 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sublingual tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Edluar&trade;: 5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermezzo&reg;: Females and males: 1.75 mg once per night as needed.",
"     <b>",
"      Note:",
"     </b>",
"     Take only if &ge;4 hours left before waking.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F236134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as tartrate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zolpimist&reg;: 5 mg/actuation (8.2 g) [contains benzoic acid, propylene glycol; cherry flavor; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambien&reg;: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edluar&trade;: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermezzo&reg;: 1.75 mg, 3.5 mg [spearmint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as tartrate: 6.25 mg, 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambien CR&reg;: 6.25 mg, 12.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F236119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral spray, sublingual tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F236197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ambien&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085906.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085906.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ambien CR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085908.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085908.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Edluar&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intermezzo&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zolpidem:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zolpimist&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7727194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     All formulations: Administer immediately before bedtime due to rapid onset of action. For faster sleep onset, do not administer with (or immediately after) a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual tablets (Edluar&trade;, Intermezzo&reg;): Examine blisterpack before use; do not use if blisters are broken, torn, or missing. Separate individual blisters at perforation; peel off top layer of paper; push tablet through foil. Place under the tongue and allow to disintegrate; do not swallow or administer with water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral spray (Zolpimist&reg;): Spray directly into the mouth over the tongue. Prior to initial use, pump should be primed by spraying 5 times. If pump is not used for at least 14 days, reprime pump with 1 spray.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablets (Ambien CR&reg;): Swallow whole; do not divide, crush, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7727188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien&reg;; Edluar&trade;: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).  Protect sublingual tablets from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien CR&reg;: Store at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); limited excursions up to 30&deg;C (86&deg;F) are permissible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpimist&reg;: Store at 25&deg;C (77&deg;F). Do not freeze. Avoid prolonged exposure to temperatures &gt;30&deg;C (86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1043345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien&reg;, Edluar&trade;, Zolpimist&reg;: Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien CR&reg;: Treatment of insomnia (with difficulty of sleep onset and/or sleep maintenance) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F236204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ambien&reg; may be confused with Abilify&reg;, Ativan&reg;, Ambi 10&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sublinox&trade; may be confused with Suboxone&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zolpidem may be confused with lorazepam, zaleplon",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ambien [U.S., Argentina, Israel] may be confused with Amyben brand name for amiodarone [Great Britain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F236202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actual frequency may be dosage form, dose, and/or age dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased, chest discomfort/pain, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, anxiety, apathy, amnesia, ataxia, attention disturbance, body temperature increased, burning sensation, confusion, depersonalization, depression, disinhibition, disorientation, dizziness, drowsiness, drugged feeling, euphoria, fatigue, fever, hallucinations, headache, hypoesthesia, insomnia, lethargy, lightheadedness, memory disorder, mood swings, sleep disorder, somnolence, stress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria, wrinkling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menorrhagia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, abdominal pain, abdominal tenderness, appetite disorder, constipation, diarrhea, dyspepsia, flatulence, gastroenteritis, gastroesophageal reflux, hiccup, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection, vulvovaginal dryness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, balance disorder, involuntary muscle contractions, myalgia, neck pain, paresthesia, psychomotor retardation, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Asthenopia, blurred vision, depth perception altered, diplopia, red eye, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis, tinnitus, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, sinusitis, throat irritation, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergy, binge eating, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agitation, anaphylaxis, anemia, angioedema, cerebrovascular disorder, cognition decreased, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), concentrating difficulty, cystitis, diaphoresis, dysphagia, dyspnea, edema, emotional lability, falling, hepatic function abnormalities, hyperglycemia, hyper-/hypotension, illusion, leukopenia, lymphadenopathy, migraine, orthostatic hypotension, paresthesia of the tongue (sublingual tablets), pruritus, renal failure (acute), scleritis, somnambulism (sleepwalking), speech disorder, stupor, sublingual erythema (sublingual tablets), syncope, tachycardia, thrombosis, urinary incontinence, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1043350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zolpidem tartrate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7727114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with sleep apnea, COPD, or respiratory compromise; myasthenia gravis; and concomitant illnesses which may affect zolpidem metabolism or hemodynamic response. Use with caution and decrease the dose in patients with hepatic impairment and in debilitated patients. Use with caution in patients with renal impairment or with a history of drug dependence.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause CNS depression impairing physical and mental capabilities; patients should be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Zolpidem should only be administered immediately prior to bedtime or after the patient has gone to bed but is having difficulty falling asleep and when the patient is able to stay in bed a full night (7-8 hours) before being active again.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The most common adverse effects observed in children include the following: Dizziness, headache, hallucinations, affect lability, enuresis, gastroenteritis, and anxiety (Blumer, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1043351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patient carefully for medical or psychiatric causes of insomnia prior to initiation of drug treatment;  failure of zolpidem to treat insomnia (after 7-10 days of therapy), a worsening of insomnia, or the emergence of behavioral changes or thinking abnormalities may indicate a medical or psychiatric illness requiring evaluation; these effects also have been reported with zolpidem use. Abnormal thinking and behavior changes may occur with sedative/hypnotic use, including decreased inhibition (eg, aggressiveness, extroversion that seems out of character); visual and auditory hallucinations, agitation, bizarre behavior, and depersonalization have been reported with zolpidem use. Hallucinations have been reported more frequently in children and adolescents receiving zolpidem for insomnia associated with ADHD than in adults (7.4% vs &le;1%). Abrupt discontinuation after prolonged use may result in withdrawal symptoms and signs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions, including anaphylaxis and angioedema, may occur; angioedema may involve the tongue, glottis, or larynx; occurrence of dyspnea, throat closing, or nausea and vomiting suggest anaphylaxis; angioedema of the throat, glottis, or larynx may result in potentially fatal airway obstruction; do not rechallenge patients who develop angioedema after receiving zolpidem. Hazardous sleep-related activities, such as sleep-driving (driving while not fully awake without any recollection of driving), preparing and eating food, and making phone calls while asleep have also been reported; increased risk of these type of events has been reported with greater than recommended zolpidem dosages as well as concomitant ethanol or CNS depressant use; amnesia may also occur; discontinue treatment in patients who report a sleep-driving episode. Effects of other sedative drugs or ethanol may be potentiated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F236189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F236128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Zolpidem. Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1043365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases maximum plasma concentration and bioavailability of immediate release, extended release, and sublingual tablets; time to peak plasma concentration is prolonged; half-life remains unchanged. Grapefruit juice may decrease the metabolism of zolpidem.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F236129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1615032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Adverse effects were noted in animal reproduction studies at doses 20-100 times the maximum recommended human dose. Severe neonatal respiratory depression has been reported when zolpidem was used at the end of pregnancy, especially when used concurrently with other CNS depressants. Studies of prenatal exposure to zolpidem have not been conducted in children. Children born of mothers taking sedative/hypnotics may be at risk for withdrawal; neonatal flaccidity has been reported in infants following maternal use of sedative/hypnotics during pregnancy. Use during pregnancy only if the benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1043383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daytime alertness; respiratory rate; behavior profile",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1043367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zolpidem, an imidazopyridine hypnotic that is structurally dissimilar to benzodiazepines, enhances the activity of the inhibitory neurotransmitter, &gamma;-aminobutyric acid (GABA), via selective agonism at the benzodiazepine-1 (BZ",
"     <sub>",
"      1",
"     </sub>",
"     ) receptor; because of its selectivity for the BZ",
"     <sub>",
"      1",
"     </sub>",
"     receptor site over the BZ",
"     <sub>",
"      2",
"     </sub>",
"     receptor site, zolpidem exhibits minimal anxiolytic, myorelaxant, and anticonvulsant properties (effects largely attributed to agonism at the BZ",
"     <sub>",
"      2",
"     </sub>",
"     receptor site).",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F7727189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1043370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release and sublingual: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Biphasic absorption; rapid initial absorption (similar to immediate release product); then provides extended concentrations in the plasma beyond 3 hours postadministration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     , apparent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-6 years: 1.8 &plusmn; 0.8 L/kg (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;6-12 years: 2.2 &plusmn; 1.7 L/kg (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: 1.2 &plusmn; 0.4 L/kg (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.54 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic methylation and hydroxylation via CYP3A4 (~60%), CYP2C9 (~22%), CYP1A2 (~14%), CYP2D6 (~3%), and CYP2C19 (~3%) to three inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years: Tablet (immediate release): 1.8 hours (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;6 years and Adolescents: Tablet (immediate release): 2.3 hours (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Spray: ~3 hours (range: 1.7-8.4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual tablet (Edluar&trade;, Intermezzo&reg;): ~3 hours (range: 1.4-6.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet (immediate release, extended release): ~2.5 hours (range: 1.4-4.5 hours); Cirrhosis: 9.9 hours (range: 4.1-25.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years: Tablet (immediate release): 0.9 hours (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;6-12 years: Tablet (immediate release): 1.1 hours (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Tablet (immediate release): 1.3 hours (Blumer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Spray: ~0.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual tablet: Edluar&trade;: ~1.4 hours; with food: ~1.8 hours; Intermezzo&reg;: 0.6-1.3 hours; with food: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: Immediate release: 1.6 hours; with food: 2.2 hours; Extended release: 1.5 hours; with food: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (48% to 67%, primarily as metabolites); feces (29% to 42%, primarily as metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance, apparent (Blumer, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-6 years: 11.7 &plusmn; 7.9 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;6-12 years: 9.7 &plusmn; 10.3 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: 4.8 &plusmn; 2 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not hemodialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1043386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/44/21189?source=see_link\">",
"      see \"Zolpidem: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of zolpidem. Avoid alcohol, other CNS depressants, and grapefruit juice. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Take dose immediately before bedtime. May also cause daytime drowsiness. May cause dry mouth. May cause hypersensitivity reactions. May cause hazardous sleep-related activities (ie, driving, preparing and eating foods, and making phone calls while not fully awake).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Armour A, Gottschlich MM, Khoury J, et al, \"A Randomized, Controlled Prospective Trial of Zolpidem and Haloperidol for Use as Sleeping Agents in Pediatric Burn Patients,\"",
"      <i>",
"       J Burn Care Res",
"      </i>",
"      , 2008, 29(1):238-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/38/26215/abstract-text/18182928/pubmed\" id=\"18182928\" target=\"_blank\">",
"        18182928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhat T, Pallikaleth SJ, and Shah N, \"Primary Insomnia Treated With Zolpidem in an 18-Month Old Child,\"",
"      <i>",
"       Indian J Psychiatry",
"      </i>",
"      , 2008,50(1):59-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Findling RL, Shih WJ, et al, \"Controlled Clinical Trial of Zolpidem for the Treatment of Insomnia Associated With Attention-Deficit/Hyperactivity Disorder in Children 6 to 17 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(5):e770-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/38/26215/abstract-text/19403468/pubmed\" id=\"19403468\" target=\"_blank\">",
"        19403468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Reed MD, Steinberg F, et al, \"Potential Pharmacokinetic Basis for Zolpidem Dosing in Children With Sleep Difficulties,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2008, 83(4):551-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/38/26215/abstract-text/17957186/pubmed\" id=\"17957186\" target=\"_blank\">",
"        17957186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13094 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26215=[""].join("\n");
var outline_f25_38_26215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15898498\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236158\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452765\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043344\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043377\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236134\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236119\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236197\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874935\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727194\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727188\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236204\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236202\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043350\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727114\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043351\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236189\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236128\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043365\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236129\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043383\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043367\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727189\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043370\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043386\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=related_link\">",
"      Zolpidem: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/44/21189?source=related_link\">",
"      Zolpidem: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_38_26216="Post-ERCP bleeding";
var content_f25_38_26216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-ERCP bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Silvano Loperfido, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Guido Costamagna, MD, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26216/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/38/26216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding was the most feared complication when therapeutic biliary endoscopy was first introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of advances in equipment and experience, it has more recently become a relatively uncommon complication of endoscopic retrograde cholangiopancreatography (ERCP), and it is mostly observed after sphincterotomy. Clinically important bleeding is uncommon with diagnostic ERCP, apart from sporadic Mallory-Weiss tears and from minor submucosal hemorrhages observed following manipulation of the papilla, particularly in patients with ampullary tumors, a bleeding diathesis, or anatomical variants such as Billroth II gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Exceptions are case reports in which serious bleeding occurs from injury to the spleen, liver, or abdominal vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/44/7882?source=see_link\">",
"     \"Rare complications of ERCP\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the risk factors and treatment of bleeding occurring following endoscopic sphincterotomy. An overview of the complications of ERCP and detailed discussions of individual complications are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-ERCP bleeding can be defined as clinically significant or nonclinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/4\">",
"     4",
"    </a>",
"    ], and can be graded as mild, moderate, or severe based upon a consensus definition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild &ndash; clinical evidence of bleeding (ie, not just endoscopic), hemoglobin drop &lt;3",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and no need for transfusion",
"     </li>",
"     <li>",
"      Moderate &ndash; need for transfusion (4 units or less), no angiographic intervention or surgery",
"     </li>",
"     <li>",
"      Severe &ndash; transfusion of 5 units or more, or intervention (angiographic or surgical)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of bleeding complications occur immediately after sphincterotomy; a delay of 24 hours up to several days is observed in other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. The possibility of late bleeding raises some concern in the present context of increasing outpatient therapeutic ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two decades ago, most series reported an incidence of post-endoscopic sphincterotomy hemorrhage of 2 to 5 percent, with a mortality of about 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/5\">",
"     5",
"    </a>",
"    ]. Lower rates (approximately 1 to 2 percent) have been found in more recent prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/1,2,6,14-18\">",
"     1,2,6,14-18",
"    </a>",
"    ]. In a review of 21 studies involving 16,855 patients between 1987 and 2003, there were a total of 226 bleeding episodes (1.3 percent), with eight deaths (0.05 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/19\">",
"     19",
"    </a>",
"    ]. Bleeding was severe in 66 of the 226 episodes (29 percent). Similar rates of bleeding (1.2 percent) were reported in two subsequent prospective studies involving a total of 7252 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1990s, a study from Hong Kong and another from Seoul reported an incidence of postsphincterotomy bleeding of 12 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The high rate of hemorrhage in these series was due to the use of more liberal definitions of bleeding compared with other studies; the definition of bleeding included patients with only endoscopic evidence of bleeding but without hemodynamic changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for post-ERCP bleeding have been suggested by retrospective and prospective studies. The following studies illustrate the findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retrospective studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three factors independently predicted post-sphincterotomy hemorrhage in a study from the United States in which major hemorrhage was observed in 10 of 189 patients (5 percent) undergoing sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/22\">",
"     22",
"    </a>",
"    ]: hemodialysis (relative risk 8.4), a prothrombin time prolonged at least two times above control (relative risk 7.8), and endoscopically observed bleeding at the time of the sphincterotomy (relative risk 5.9).",
"   </p>",
"   <p>",
"    A series from Hong Kong included 983 patients undergoing sphincterotomy for common duct stones of whom 119 (12 percent) developed post sphincterotomy bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/20\">",
"     20",
"    </a>",
"    ]. Independent predictors of bleeding included: stone impaction at the papilla, the presence of a periampullary diverticulum, and extension of a previous sphincterotomy.",
"   </p>",
"   <p>",
"    Billroth II anatomy was the only variable associated with clinically significant bleeding in a study from a single center in France in which clinically significant bleeding was observed in 0.65 percent of 2444 patients undergoing sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5415?source=see_link\">",
"     \"ERCP after Billroth II reconstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another series focused on 52 patients with cirrhosis of varying severity undergoing sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/23\">",
"     23",
"    </a>",
"    ]. The presence of portal hypertension, coagulopathy, and Child-Pugh score (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) were not associated with bleeding risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/23\">",
"     23",
"    </a>",
"    ]. However, complications in patients with Child class C were more serious than those with Child class A or B cirrhosis; all four early deaths, including one from post-sphincterotomy bleeding, occurred in Child C patients.",
"   </p>",
"   <p>",
"    It has been hypothesized that the length of a sphincterotomy is a predictor of hemorrhage. This hypothesis is supported by the observation that clinically significant bleeding occurs more frequently after sphincterotomy for biliary stones [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6,8\">",
"     6,8",
"    </a>",
"    ], with to stenting (which requires a smaller sphincterotomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prospective studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following variables were independent predictors of bleeding in a study from North America involving 2347 patients from 17 institutions undergoing sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6\">",
"     6",
"    </a>",
"    ]: coagulopathy before the procedure, anticoagulation within three days after procedure, cholangitis before the procedure, mean case volume of endoscopist less than or equal to one per week, and bleeding during the procedure. A similarly designed study involving 2769 patients from nine centers in Italy also found that case volume (ie, &lt;200 annual ERCPs) was a significant predictor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/2\">",
"     2",
"    </a>",
"    ]. Precut sphincterotomy and stenosis of the papilla of Vater were independently associated with hemorrhage in another report also from nine Italian centers involving 2103 patients undergoing diagnostic and therapeutic ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/14\">",
"     14",
"    </a>",
"    ]. Location of the papilla within or at the lower rim of a diverticulum was a significant risk factor for bleeding in a prospective study of 242 patients undergoing sphincterotomy for bile duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/25\">",
"     25",
"    </a>",
"    ]. In a study from Seoul in which bleeding was observed in 10 percent of 1304 cases, independent risk factors included rapid cutting (the so-called \"zipper\" cut), and the use of needle-knife sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/21\">",
"     21",
"    </a>",
"    ]. Coagulopathy, the presence of an impacted stone, and ampullary cancer contributed to the severity of hemorrhage.",
"   </p>",
"   <p>",
"    A study of 506 patients found that the only variables predicting bleeding were the presence of thrombocytopenia, an elevated plasma creatinine concentration, and an elevated international normalized ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/26\">",
"     26",
"    </a>",
"    ]. Bleeding immediately after sphincterotomy (or the pattern of bleeding) did not predict delayed bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of bleeding can be minimized by identifying patients at risk, taking measures to optimize coagulation abnormalities, and by careful technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prothrombin time and platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prothrombin time and platelet count should be obtained routinely before ERCP since the need for sphincterotomy cannot always be anticipated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6\">",
"     6",
"    </a>",
"    ]. A platelet count exceeding 50,000 to 80,000 per mm3, and an international normalized ratio &lt;1.2 are generally found to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6,23,27-29\">",
"     6,23,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Identifying patients at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, sphincterotomy is contraindicated in patients with severe coagulation disorders, such as occur in patients with advanced liver disease, in patients with hematologic diseases, and in patients with disorders of hemostasis, such as hemophilia and von Willebrand disease. Postprocedure observation should be extended in patients with portal hypertension or cirrhosis. Patients with known platelet dysfunction (such as patients on hemodialysis) should receive appropriate preventive measures, which may include infusion of DDAVP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the risk factors discussed above, caution is advisable in patients with a papillary tumor. This condition is probably a risk factor for bleeding based upon pathophysiologic and technical considerations and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Optimizing coagulation abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Correction of clotting defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy remains regarding the appropriate use of platelet and coagulation factor transfusions in high-risk patients. Correction of clotting defects with fresh-frozen plasma, vitamin K, or platelet transfusion has permitted successful endoscopic sphincterotomy in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antiplatelet drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , other NSAIDs, and new platelet inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ) have the potential to increase the risk of bleeding induced by gastrointestinal endoscopic procedures, but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Recommendations regarding these drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Anticoagulation reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the anticoagulated patient, the decision to reverse anticoagulation and the extent of anticoagulation reversal should be individualized based upon the relative risk of the procedure and underlying condition. The timing of reintroduction of anticoagulation also should be individualized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endoscopic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the risk of bleeding is increased when sphincterotomy is performed in settings with relatively inexperienced endoscopists or when the endoscopy unit workload is low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. These observations underscore that technique is of primary importance. Improvement in the endoscopic methods may explain the slight decrease in the sphincterotomy-induced bleeding rate observed during the last two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemorrhage can be prevented or limited by proper orientation of the wire, avoidance of \"zipper\" cuts and unnecessarily long cuts, and judicious use of the electrocautery current [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/33\">",
"     33",
"    </a>",
"    ]. Optimal electrocautery settings are uncertain because of a tradeoff in the risk of pancreatitis versus bleeding. Pure cut electrocautery current is associated with an increase in the frequency of localized bleeding, which may temporarily obscure the view and interfere with the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some endoscopists combine pure cut and blended current in sequence, starting with pure cut and completing the sphincterotomy with blended current [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/35\">",
"     35",
"    </a>",
"    ]. However, this approach did not reduce the rate of clinically relevant post-sphincterotomy bleeding in two comparative studies from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/36\">",
"     36",
"    </a>",
"    ] and Greece [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocut is a method of producing current using the Erbe, Inc cautery device by automatically varying the intensity of current and current blend according to tissue resistance. A randomized controlled trial from Germany found a reduced rate of minor bleeding following sphincterotomy compared with a conventional current generator [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/38\">",
"     38",
"    </a>",
"    ]. There were no episodes of moderate or severe bleeding. Similar conclusions were reached in a large retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/39\">",
"     39",
"    </a>",
"    ] and in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/40\">",
"     40",
"    </a>",
"    ]. Endoscopically observed bleeding occurred less often in the Erbe group, but there were no significant differences in clinically evident bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10214?source=see_link\">",
"     \"Standard biliary sphincterotomy technique: The cutting edge\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For treatment of small bile duct stones in patients with hemostatic disorders, endoscopic papillary balloon dilation (EBD) can reduce the risk of bleeding compared with standard sphincterotomy. However, EBD has been associated with an increased risk of pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A newer technique of combining a small sphincterotomy with balloon dilation may reduce the risk of perforation and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of a covered sphincterotome to decrease the risk of bleeding was examined in a prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/42\">",
"     42",
"    </a>",
"    ]. The rationale for using such a device is to provide more controlled cutting and to avoid \"zipper cuts.\" Use of a partially covered sphincterotome was not associated with a lower frequency of post-endoscopic sphincterotomy bleeding compared with an uncovered sphincterotome.",
"   </p>",
"   <p>",
"    Submucosal injections have also been studied for the prevention of postsphincterotomy bleeding. In a randomized prospective trial, prophylactic submucosal injection of hypertonic saline-epinephrine seemed to be effective for the prevention of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional studies are needed to determine if this technique should routinely be employed for patients at increased for bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-sphincterotomy bleeding often stops spontaneously and is rarely life-threatening, except in patients with a bleeding diathesis. Most clinically relevant hemorrhages can be managed with medical treatment and endoscopic therapy, which should be carried out without delay in patients who have immediate bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Angiography or surgery is usually reserved for patients with refractory bleeding. In one study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6\">",
"     6",
"    </a>",
"    ], surgery was required in only 2 of 48 bleeding patients (0.08 percent of the overall series). In the Italian study involving 1827 patients, only 2 of 21 patients (0.11 percent) with clinically relevant hemorrhage required surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/2\">",
"     2",
"    </a>",
"    ]. The decrease in surgery during the past two decades was illustrated in a large historical series from the Erlangen University in Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/1\">",
"     1",
"    </a>",
"    ]. Between 1973 and 1997, a shift was observed from surgical management in 41 percent, to conservative management in 100 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of endoscopic techniques are used to control bleeding, singularly or in combination: injection therapy, mechanical methods, and thermal methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Injection therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injection therapy with epinephrine &mdash; The most used and generally effective endoscopic intervention is injection therapy with diluted epinephrine (1:10,000) through a sclerotherapy needle [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]. Injection of sclerosing agents in combination with epinephrine has also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/10,16,21,44-46\">",
"       10,16,21,44-46",
"      </a>",
"      ], but",
"      <strong>",
"       extreme caution is required when injecting sclerosants",
"      </strong>",
"      due to the risk of non-selective inflammatory or necrotic effects, which have been documented when these agents have been used to treat bleeding peptic ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The efficacy of injection therapy was illustrated in a study that included 1304 patients, 10 percent of whom developed bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/21\">",
"       21",
"      </a>",
"      ]. Bleeding was initially treated by spraying the area with epinephrine followed by epinephrine injection if bleeding persisted. Patients with a visible vessel were treated with combination therapy with epinephrine injection and absolute alcohol injection (mean volume 0.3 mL). Initial hemostasis was achieved in all patients. However, rebleeding occurred in eight (all of whom initially had moderate to severe bleeding); bleeding was controlled in all these patients with repeated endoscopic therapy.",
"      <br/>",
"      <br/>",
"      In a retrospective study, epinephrine injection alone was as effective as epinephrine injection combined with thermotherapy for the management of delayed post-endoscopic sphincterotomy bleeding, but this study had severe limitations. One of the primary limitations is that it is not clear whether the patients were undergoing dual therapy because of epinephrine monotherapy failure [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Injection therapy with fibrin sealant &mdash; The injection of fibrin sealant, a two component adhesive consisting of human fibrin and thrombin with the addition of coagulation factor XIII, has also been successfully used to stop post-sphincterotomy bleeding in the case of rebleeding after injection therapy with epinephrine [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/50\">",
"       50",
"      </a>",
"      ]. The injection of a fibrin sealant has potential advantages over sclerosants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"       \"Fibrin sealant\"",
"      </a>",
"      .) However, a number of drawbacks should be considered: difficulty of preparation and injection, high cost, potential risk of transmission of infection, and possible occlusion of the pancreatic orifice if the injection is not carefully targeted in the upper rim of the sphincterotomy. It is advisable to secure biliary and pancreatic outflow by placing pancreatic and biliary stents [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Mechanical methods",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoclip &ndash; When injection therapy with epinephrine fails or bleeding recurs, hemostasis can be achieved by precise placement of one or more hemoclips at the bleeding site [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. However, clips may be difficult to apply with the side-viewing endoscope in the setting of active bleeding. In addition, clips may be inadvertently applied to the pancreatic orifice with the associated risk of pancreatitis.",
"     </li>",
"     <li>",
"      Balloon tamponade &ndash; Balloon tamponade can be achieved with a standard stone extraction balloon catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/6,54\">",
"       6,54",
"      </a>",
"      ]. The efficacy of this method has not been well-studied.",
"     </li>",
"     <li>",
"      Temporary self-expandable metal stent &ndash; Temporary placement of a fully self-expandable metal stent resulted in immediate hemostasis in five patients with post-endoscopic sphincterotomy bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/55\">",
"       55",
"      </a>",
"      ]. This form of mechanical tamponade can be considered in select situations, such as in patients with bleeding not responding to other endoscopic measures. The authors note that this method has a number of drawbacks, and stent migration is the main concern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Thermal methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of electrocautery current is more difficult than injection therapy, but can be attempted with the sphincterotome wire [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/5\">",
"     5",
"    </a>",
"    ] or with an electrocautery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/56\">",
"     56",
"    </a>",
"    ] or heater probe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/57\">",
"     57",
"    </a>",
"    ] if a visible vessel or a specific bleeding point can be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/28\">",
"     28",
"    </a>",
"    ]. Argon plasma coagulation is another thermal method that can be used cautiously to achieve permanent hemostasis after injection therapy with epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleeding usually starts from the side of the cut (more often on the right side). An extension of the sphincterotomy has been suggested to allow full retraction of a partially severed vessel in cases when brisk bleeding occurs during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/59\">",
"     59",
"    </a>",
"    ]. However, sphincterotomy should be fully completed only if required for stone removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    was effective in stopping bleeding in a patient with a coagulopathy who had delayed bleeding after sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H126520251\">",
"    <span class=\"h2\">",
"     Vasoactive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion of terlipressin in four patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/61\">",
"     61",
"    </a>",
"    ] and infusion of nitroglycerin in another case report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/62\">",
"     62",
"    </a>",
"    ] were effective in controlling hemobilia during therapeutic ERCP in patients with portal biliopathy (intra- and extrahepatic bile duct abnormalities that are a result of portal hypertension).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Angiographic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac or superior mesenteric angiography with transcatheter infusion of vasopressin or embolization of the bleeding artery can be effective, but is uncommonly performed as underscored by the paucity of data on this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/8,63\">",
"     8,63",
"    </a>",
"    ]. It is also worth remembering that arterial embolization is technically difficult and may cause infarction of abdominal organs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/64\">",
"     64",
"    </a>",
"    ], although studies show a reduction of risk of bowel infarction due to technical developments and increased experience of the interventionalists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the need for surgery has decreased during the past two decades because of success with endoscopic methods [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/1\">",
"     1",
"    </a>",
"    ]. The most commonly performed operation involves conversion of the sphincterotomy into a sutured sphincteroplasty and oversewing the bleeding artery at the apex of the sphincterotomy. If anatomic changes make direct access to the ampulla through the duodenal wall impossible, a Fogarty catheter can be inserted into the common bile duct (either through the cystic duct or a choledochotomy) permitting balloon tamponade of the bleeding point [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/65\">",
"     65",
"    </a>",
"    ]. In older series, surgery was associated with post-operative mortality rates as high as 50 percent, largely because many of the patients treated by ERCP were considered to be too ill for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infusion of a topical gelatin matrix-thrombin hemostatic agent into the distal portion of the common bile duct during urgent surgical exploration was effective in a patient with life-threatening bleeding after endoscopic sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26216/abstract/67\">",
"     67",
"    </a>",
"    ]. Further experience is needed to confirm the efficacy of this topical hemostatic agent in cases of bleeding after ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=see_link\">",
"     \"Overview of topical hemostatic agents used in the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"       \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70566318\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically important bleeding is uncommon with diagnostic ERCP. Bleeding is most often seen following sphincterotomy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-ERCP bleeding can be defined as clinically significant or nonclinically significant and can be graded as mild, moderate, or severe based upon a consensus definition (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and grading'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild: clinical evidence of bleeding (ie, not just endoscopic), hemoglobin drop &lt;3",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and no need for transfusion",
"     </li>",
"     <li>",
"      Moderate: need for transfusion (4 units or less), no angiographic intervention or surgery",
"     </li>",
"     <li>",
"      Severe: transfusion 5 units or more or intervention (angiographic or surgical)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall risk of clinical hemorrhage in patients undergoing sphincterotomy is approximately 1 to 2 percent. Most bleeding episodes are mild to moderate in severity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Risk factors include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient factors: coagulopathy, anticoagulation within three days after procedure, Child class C cirrhosis, renal failure on ongoing hemodialysis, bleeding during the procedure, stone as an indication for the procedure, and cholangitis before the procedure.",
"     </li>",
"     <li>",
"      Anatomical factors: peripapillary diverticulum, Billroth II gastrectomy, stenosis of the orifice of the papilla of Vater, stone impaction.",
"     </li>",
"     <li>",
"      Technical factors: sphincterotomy length, extension of previous sphincterotomy, zipper cut, needle-knife sphincterotomy, low case volume of the endoscopist and endoscopy unit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of bleeding can be minimized by identifying patients at risk, taking measures to optimize coagulation abnormalities, and by careful technique. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-sphincterotomy bleeding often stops spontaneously and is rarely life-threatening, except in patients with a bleeding diathesis. Most clinically relevant hemorrhages can be managed with medical treatment and endoscopic therapy, which should be carried out without delay in patients who have immediate bleeding. Angiography or surgery is usually reserved for patients with refractory bleeding. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/1\">",
"      Rabenstein T, Schneider HT, Hahn EG, Ell C. 25 years of endoscopic sphincterotomy in Erlangen: assessment of the experience in 3498 patients. Endoscopy 1998; 30:A194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/2\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/3\">",
"      Lin LF, Siauw CP, Ho KS, Tung JC. ERCP in post-Billroth II gastrectomy patients: emphasis on technique. Am J Gastroenterol 1999; 94:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/4\">",
"      Ferreira LE, Baron TH. Post-sphincterotomy bleeding: who, what, when, and how. Am J Gastroenterol 2007; 102:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/5\">",
"      Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/6\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/7\">",
"      Finnie IA, Tobin MV, Morris AI, Gilmore IT. Late bleeding after endoscopic sphincterotomy for bile duct calculi. BMJ 1991; 302:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/8\">",
"      Boujaoud&eacute; J, Pelletier G, Fritsch J, et al. Management of clinically relevant bleeding following endoscopic sphincterotomy. Endoscopy 1994; 26:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/9\">",
"      Gholson CF, Favrot D, Vickers B, et al. Delayed hemorrhage following endoscopic retrograde sphincterotomy for choledocholithiasis. Dig Dis Sci 1996; 41:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/10\">",
"      V&aacute;sconez C, Llach J, Bordas JM, et al. Injection treatment of hemorrhage induced by endoscopic sphincterotomy. Endoscopy 1998; 30:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/11\">",
"      Ferreira LE, Fatima J, Baron TH. Clinically significant delayed postsphincterotomy bleeding: a twelve year single center experience. Minerva Gastroenterol Dietol 2007; 53:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/12\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc 1999; 49:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/13\">",
"      Ho KY, Montes H, Sossenheimer MJ, et al. Features that may predict hospital admission following outpatient therapeutic ERCP. Gastrointest Endosc 1999; 49:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/14\">",
"      Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/15\">",
"      Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/16\">",
"      Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. Gastrointest Endosc 2004; 60:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/17\">",
"      Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/18\">",
"      Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/19\">",
"      Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/20\">",
"      Leung JW, Chan FK, Sung JJ, Chung S. Endoscopic sphincterotomy-induced hemorrhage: a study of risk factors and the role of epinephrine injection. Gastrointest Endosc 1995; 42:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/21\">",
"      Kim HJ, Kim MH, Kim DI, et al. Endoscopic hemostasis in sphincterotomy-induced hemorrhage: its efficacy and safety. Endoscopy 1999; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/22\">",
"      Nelson DB, Freeman ML. Major hemorrhage from endoscopic sphincterotomy: risk factor analysis. J Clin Gastroenterol 1994; 19:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/23\">",
"      Prat F, Tennenbaum R, Ponsot P, et al. Endoscopic sphincterotomy in patients with liver cirrhosis. Gastrointest Endosc 1996; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/24\">",
"      Margulies C, Siqueira ES, Silverman WB, et al. The effect of endoscopic sphincterotomy on acute and chronic complications of biliary endoprostheses. Gastrointest Endosc 1999; 49:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/25\">",
"      Boender J, Nix GA, de Ridder MA, et al. Endoscopic papillotomy for common bile duct stones: factors influencing the complication rate. Endoscopy 1994; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/26\">",
"      Wilcox CM, Canakis J, M&ouml;nkem&uuml;ller KE, et al. Patterns of bleeding after endoscopic sphincterotomy, the subsequent risk of bleeding, and the role of epinephrine injection. Am J Gastroenterol 2004; 99:244.",
"     </a>",
"    </li>",
"    <li>",
"     Henning H, Lightdale CJ, Look D. Contraindications &ndash; Coagulation disorders. In: Color Atlas of diagnostic Laparoscopy, Stuttgart, Thieme, New York 1994. p.17.",
"    </li>",
"    <li>",
"     Sherlock S, Dooley J. Needle biopsy of the liver. In: Diseases of the Liver and Biliary System, 9th edition, Blackwell, Oxford 1993. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/29\">",
"      Sherman S, Hawes RH, Nisi R, Lehman GA. Endoscopic sphincterotomy-induced hemorrhage: treatment with multipolar electrocoagulation. Gastrointest Endosc 1992; 38:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/30\">",
"      Bickerstaff KI, Berry AR, Chapman RW, Britton BJ. Endoscopic sphincterotomy for the palliation of ampullary carcinoma. Br J Surg 1990; 77:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/31\">",
"      Kimchi NA, Broide E, Scapa E, Birkenfeld S. Antiplatelet therapy and the risk of bleeding induced by gastrointestinal endoscopic procedures. A systematic review of the literature and recommendations. Digestion 2007; 75:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/32\">",
"      Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/33\">",
"      Ratani RS, Mills TN, Ainley CC, Swain CP. Electrophysical factors influencing endoscopic sphincterotomy. Gastrointest Endosc 1999; 49:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/34\">",
"      Verma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastrointest Endosc 2007; 66:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/35\">",
"      Pasricha P. Current news about sphincterotomy-induced pancreatitis: does electrocautery setting make a difference? Gastroenterology 1998; 115:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/36\">",
"      Gorelick A, Cannon M, Barnett J, et al. First cut, then blend: an electrocautery technique affecting bleeding at sphincterotomy. Endoscopy 2001; 33:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/37\">",
"      Stefanidis G, Karamanolis G, Viazis N, et al. A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. Gastrointest Endosc 2003; 57:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/38\">",
"      Kohler A, Maier M, Benz C, et al. A new HF current generator with automatically controlled system (Endocut mode) for endoscopic sphincterotomy--preliminary experience. Endoscopy 1998; 30:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/39\">",
"      Perini RF, Sadurski R, Cotton PB, et al. Post-sphincterotomy bleeding after the introduction of microprocessor-controlled electrosurgery: does the new technology make the difference? Gastrointest Endosc 2005; 61:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/40\">",
"      Norton ID, Petersen BT, Bosco J, et al. A randomized trial of endoscopic biliary sphincterotomy using pure-cut versus combined cut and coagulation waveforms. Clin Gastroenterol Hepatol 2005; 3:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/41\">",
"      Attasaranya S, Cheon YK, Vittal H, et al. Large-diameter biliary orifice balloon dilation to aid in endoscopic bile duct stone removal: a multicenter series. Gastrointest Endosc 2008; 67:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/42\">",
"      Katsinelos P, Paroutoglou G, Kountouras J, et al. Partially covered vs uncovered sphincterotome and post-endoscopic sphincterotomy bleeding. World J Gastroenterol 2010; 16:5077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/43\">",
"      Matsushita M, Takakuwa H, Shimeno N, et al. Prophylactic injection of hypertonic saline-epinephrine oral to the papilla for prevention of postsphincterotomy bleeding. J Clin Gastroenterol 2010; 44:e167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/44\">",
"      Grimm H, Soehendra N. [Infiltrating injection in the management of post-papillotomy hemorrhages]. Dtsch Med Wochenschr 1983; 108:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/45\">",
"      Costamagna G. What to do when the papilla bleeds after endoscopic sphincterotomy. Endoscopy 1998; 30:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/46\">",
"      Park DH, Kim MH, Lee SK, et al. Endoscopic sphincterotomy vs. endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy. Gastrointest Endosc 2004; 60:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/47\">",
"      Loperfido S, Patelli G, La Torre L. Extensive necrosis of gastric mucosa following injection therapy of bleeding peptic ulcer. Endoscopy 1990; 22:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/48\">",
"      Chester JF, Hurley PR. Gastric necrosis: a complication of endoscopic sclerosis for bleeding peptic ulcer. Endoscopy 1990; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/49\">",
"      Tsou YK, Lin CH, Liu NJ, et al. Treating delayed endoscopic sphincterotomy-induced bleeding: epinephrine injection with or without thermotherapy. World J Gastroenterol 2009; 15:4823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/50\">",
"      Born P, Ott R, R&ouml;sch T. Endoscopic hemostasis using fibrin sealant for postsphincterotomy bleeding: report of two cases. Gastrointest Endosc 2000; 51:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/51\">",
"      Mutignani M, Seerden T, Tringali A, et al. Endoscopic hemostasis with fibrin glue for refractory postsphincterotomy and postpapillectomy bleeding. Gastrointest Endosc 2010; 71:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/52\">",
"      Baron TH, Norton ID, Herman L. Endoscopic hemoclip placement for post-sphincterotomy bleeding. Gastrointest Endosc 2000; 52:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/53\">",
"      Katsinelos P, Paroutoglou G, Beltsis A, et al. Endoscopic hemoclip placement for postsphincterotomy bleeding refractory to injection therapy: report of two cases. Surg Laparosc Endosc Percutan Tech 2005; 15:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/54\">",
"      Mosca S, Galasso G. Immediate and late bleeding after endoscopic sphincterotomy. Endoscopy 1999; 31:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/55\">",
"      Shah JN, Marson F, Binmoeller KF. Temporary self-expandable metal stent placement for treatment of post-sphincterotomy bleeding. Gastrointest Endosc 2010; 72:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/56\">",
"      Katsinelos P, Kountouras J, Chatzimavroudis G, et al. Endoscopic hemostasis using monopolar coagulation for postendoscopic sphincterotomy bleeding refractory to injection treatment. Surg Laparosc Endosc Percutan Tech 2010; 20:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/57\">",
"      Kuran S, Parlak E, Oguz D, et al. Endoscopic sphincterotomy-induced hemorrhage: treatment with heat probe. Gastrointest Endosc 2006; 63:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/58\">",
"      Waye JD, Goh KL, Huibregtse K, et al. Endoscopic sphincterotomy: 2002. Gastrointest Endosc 2002; 55:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/59\">",
"      Leese T, Neoptolemos JP, Carr-Locke DL. Successes, failures, early complications and their management following endoscopic sphincterotomy: results in 394 consecutive patients from a single centre. Br J Surg 1985; 72:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/60\">",
"      Romero-Castro R, Jim&eacute;nez-S&aacute;enz M, Pellicer-Bautista F, Herrer&iacute;as-Guti&eacute;rrez JM. Refractory bleeding after endoscopic sphincterotomy: a new indication for recombinant factor VII therapy? Am J Gastroenterol 2004; 99:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/61\">",
"      Tyagi P, Sachdeva S, Agarwal AK, Puri AS. Terlipressin in control of acute hemobilia during therapeutic ERCP in patient with portal biliopathy. Surg Laparosc Endosc Percutan Tech 2009; 19:e198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/62\">",
"      Sharma M, Babu CS, Dhiman RK, Chawla Y. Induced hypotension in the management of acute hemobilia during therapeutic ERCP in a patient with portal biliopathy (with videos). Gastrointest Endosc 2010; 72:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/63\">",
"      Saeed M, Kadir S, Kaufman SL, et al. Bleeding following endoscopic sphincterotomy: angiographic management by transcatheter embolization. Gastrointest Endosc 1989; 35:300.",
"     </a>",
"    </li>",
"    <li>",
"     Walker TG, Waltman AC. Angiographic diagnosis and therapy of upper gastrointestinal hemorrhage. In: Therapeutic Endoscopy and Radiology of the Gut, Bennet JR, Hunt RH (Eds), Williams and Wilkins, Baltimore 1990. p.167.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/65\">",
"      Bardaxoglou E, Campion JP, Maddern G, et al. A simple method to control intractable bleeding after endoscopic sphincterotomy. Am J Surg 1994; 167:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/66\">",
"      Goodall RJ. Bleeding after endoscopic sphincterotomy. Ann R Coll Surg Engl 1985; 67:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26216/abstract/67\">",
"      Dimitroulis D, Antoniou E, Karidis NP, et al. Surgical control of life-threatening post-ERCP bleeding with a gelatin matrix-thrombin hemostatic agent. Int J Surg Case Rep 2012; 3:471.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 636 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26216=[""].join("\n");
var outline_f25_38_26216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H70566318\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retrospective studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prospective studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prothrombin time and platelet count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Identifying patients at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Optimizing coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Correction of clotting defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antiplatelet drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Anticoagulation reversal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Injection therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Mechanical methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Thermal methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H126520251\">",
"      Vasoactive drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Angiographic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70566318\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5415?source=related_link\">",
"      ERCP after Billroth II reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=related_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=related_link\">",
"      Overview of topical hemostatic agents used in the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=related_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/44/7882?source=related_link\">",
"      Rare complications of ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10214?source=related_link\">",
"      Standard biliary sphincterotomy technique: The cutting edge",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_38_26217="Pyoderma gangrenosum - early lesion";
var content_f25_38_26217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59459%7ERHEUM%2F53733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59459%7ERHEUM%2F53733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early lesion of pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pustule on an erythematous base represents an early lesion of pyoderma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early lesion in pyoderma gangrenosum presenting as a pustular and violaceous plaque with incipient breakdown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26217=[""].join("\n");
var outline_f25_38_26217=null;
var title_f25_38_26218="Donor selection for hematopoietic cell transplantation";
var content_f25_38_26218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Donor selection for hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/38/26218/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26218/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/38/26218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26218/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/38/26218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/38/26218/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/38/26218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of a donor is a critical element contributing to the success of a hematopoietic cell transplant (HCT). There are several possible sources for these cells:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An identical twin (syngeneic, HLA identical)",
"     </li>",
"     <li>",
"      A sibling, relative, or unrelated donor (allogeneic, which can be HLA identical, haploidentical, or mismatched)",
"     </li>",
"     <li>",
"      The patient (autologous, HLA identical)",
"     </li>",
"     <li>",
"      Umbilical cord blood (allogeneic, which can be HLA identical, haploidentical, or mismatched)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide an overview of the general issues involved in donor selection for HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The decision as to which donor source to utilize depends to a large degree upon the clinical situation and the approaches employed at the individual transplant center. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant donors must be in generally good health without other comorbid conditions. The donor must have a performance status that will permit the safe collection of the cells, either by bone marrow (BM) or peripheral blood progenitor cell (PBPC) collection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the donor must have adequate cardiac, pulmonary, hepatic, and renal function. If being considered for BM collection, the donor must be able to tolerate anesthesia (either general or regional). Pediatric donors are only utilized for autologous collection or donation to siblings. Donors with ongoing malignancies or a history of a malignant condition other than minor skin cancers (eg, basal cell carcinomas) are generally excluded from further consideration. For sibling donors with a history of a malignant condition, a five-year disease-free period without recurrence is usually considered adequate for subsequent collection.",
"   </p>",
"   <p>",
"    Viral serologic studies are performed on all donors. Donors must be negative for both anti-HIV antibodies and HIV RNA. Serologic tests for hepatitis B and C are also required at most transplant centers. Donors with active viral hepatitis are usually excluded, although exceptions are occasionally made with sibling donors, depending upon the clinical urgency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/5\">",
"     5",
"    </a>",
"    ]. In certain circumstances, antiviral therapy may be considered if time permits for an adequate course [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/6\">",
"     6",
"    </a>",
"    ]. Testing for sickle cell disease, exposure to syphilis, West Nile virus, and other potential pathogens are required by some States and Regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link&amp;anchor=H3#H3\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Donor selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following additional studies are routinely performed on hematopoietic cell donors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination, including a careful history of past bleeding events and allergies",
"     </li>",
"     <li>",
"      Past surgical and obstetrical history",
"     </li>",
"     <li>",
"      Complete blood count with platelet count",
"     </li>",
"     <li>",
"      Serum creatinine and electrolytes and liver function studies",
"     </li>",
"     <li>",
"      Serologic studies for cytomegalovirus (CMV) and herpes viruses",
"     </li>",
"     <li>",
"      ABO blood typing",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that additional testing, including bone marrow aspiration, be performed in selected donors in order to minimize the risk of donor-derived malignancy in the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, in two series in which donors had bone marrow examinations performed, hematologic malignancies were noted in zero and 3 percent of the donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. The relative rarity of these disorders makes it hard to recommend such testing except in highly unusual circumstances, such as a family history of malignancy or other transferable disorder. This is not a general practice that we employ unless there is an abnormality identified by more routine testing that would prompt a bone marrow examination. An exception is for related donors for patients with chronic lymphocytic leukemia (CLL) where familial concordance is relatively high. Typically, peripheral blood assessment for the presence of CD5+CD19+ lymphocytes is considered adequate to rule out monoclonal B cell lymphocytosis with a CLL-phenotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35354?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Familial disorders leading to AML'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Monoclonal B-cell lymphocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effect of donor age and other characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;While retrospective analyses have suggested that increasing donor age may be associated with increased transplant-related complications, donor age is only relevant when there are multiple donors that vary widely in age.",
"   </p>",
"   <p>",
"    The effect of donor age was best demonstrated in a retrospective analysis from the National Marrow Donor Program of 6978 unrelated bone marrow transplants performed from 1987 to 1999 that evaluated the effects of various donor characteristics (eg, age, sex, CMV serologic status, ABO compatibility, race, and parity) on recipient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/10\">",
"     10",
"    </a>",
"    ]. Mobilized peripheral blood transplants were excluded from this analysis. The following major findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age was the only donor trait significantly associated with overall and disease-free survival. Five-year overall survival rates were 33, 29, and 25 percent for donors aged 18 to 30, 31 to 45, and &gt;45 years, respectively. A similar effect was observed among HLA-mismatched cases.",
"     </li>",
"     <li>",
"      The cumulative incidence of grade III or IV acute graft versus host disease (GVHD) were 30, 34, and 34 percent for donors aged 18 to 30, 31 to 45, and &gt;45 years, respectively. The corresponding incidences of chronic GVHD at two years were 44, 48, and 49 percent, respectively.",
"     </li>",
"     <li>",
"      Recipients with female donors who had undergone multiple pregnancies had a higher rate of chronic GVHD (54 percent) than recipients with male donors (44 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have found that younger donors are associated with lower incidences of secondary graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/11\">",
"     11",
"    </a>",
"    ], B cell lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/12\">",
"     12",
"    </a>",
"    ], and obstructive lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/13\">",
"     13",
"    </a>",
"    ] following allogeneic transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032308\">",
"    <span class=\"h2\">",
"     Donor use of statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins may alter immune function in ways that may contribute to their antiatherosclerotic effects and appear to reduce immune responses to auto- and allo-antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/14\">",
"     14",
"    </a>",
"    ]. Of relevance, the use of statins reduced the mortality related to acute GVHD in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/15\">",
"     15",
"    </a>",
"    ] and was associated with a trend towards decreased risk of grades II-IV acute GVHD in a retrospective analysis of 67 patients who had received allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional, larger retrospective analysis of allogeneic HCT outcomes was performed according to statin use by 567 patients with hematologic malignancies and their HLA identical sibling donors. Compared with the 464 allografts where neither the donor nor the recipient was treated with a statin at the time of HCT, statin use by the HCT donor and not the recipient was associated with a significantly decreased risk of grades III-IV acute GVHD (HR 0.28; 95% CI 0.1-0.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/14\">",
"     14",
"    </a>",
"    ]. Statin-associated GVHD protection was limited to those patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based postgrafting immunosuppression, and was not observed among those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    As this was a retrospective analysis, many questions remain concerning statin use by the HCT donor and its possible protective effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IDENTICAL TWIN DONORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients who are candidates for hematopoietic cell transplantation have an identical twin as a potential donor. These patients do not require post-transplant immunosuppression and do not develop graft-versus-host disease (GVHD). However, they are at a higher risk of relapse of the underlying malignant disease than similar patients transplanted with HLA-matched but nonidentical sibling donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/17\">",
"     17",
"    </a>",
"    ]. This is especially true for patients transplanted for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), less so for patients with acute lymphoblastic leukemia (ALL) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/18\">",
"     18",
"    </a>",
"    ], and has not been demonstrated in patients transplanted for non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships were illustrated in a review from 163 transplant centers which compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/18\">",
"     18",
"    </a>",
"    ]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than allogeneic transplants in AML (52 versus 16 percent) and CML (40 versus 7 percent); the graft-versus-leukemia (GVL) effect was less apparent and not statistically significant in ALL (36 versus 26 percent).",
"   </p>",
"   <p>",
"    The reason for this disparity is related to the ability of the donor lymphocytes to recognize the recipient tumor cells, ie, a GVL reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/20\">",
"     20",
"    </a>",
"    ]. Interestingly, survival was similar with the two types of transplants because the increased incidence of leukemia relapse with identical twin transplants was counterbalanced by less treatment-related mortality, in particular GVHD.",
"   </p>",
"   <p>",
"    Molecular scrutiny of the blood of the healthy twin (and potential transplant donor) is particularly relevant if the malignant clone in the unhealthy twin may have been present in utero, as has been shown for acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Under such circumstances, identical twins with a shared placental circulation may be harboring the identical malignant clone, with one twin developing clinically evident leukemia in advance of the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MATCHED RELATED DONORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Related donors are generally siblings since they have the opportunity to inherit the same human leukocyte antigen (HLA) genes located on chromosome 6. There is a 25 percent chance that a given sibling will be HLA-matched at the A, B, and DR loci which are the principal loci evaluated using serologic methods (",
"    <a class=\"graphic graphic_figure graphicRef72917 \" href=\"UTD.htm?42/10/43169\">",
"     figure 1",
"    </a>",
"    ). In matched siblings, serologic typing is adequate, since a match at these loci makes it highly likely that the same genes were inherited from the parents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HLA-matched sibling donors are generally the preferred donor source for an allogeneic transplant. It is unlikely that matched related donors will be anything other than siblings unless the parents happen to have very common haplotypes or there has been intermarrying among families, such that first cousins might be fully HLA-matched.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MISMATCHED RELATED DONORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032398\">",
"    <span class=\"h2\">",
"     Single antigen mismatched siblings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most centers, a complete match at the HLA-A, -B and -DR loci is required for that individual to be used as a related donor. In some cases, siblings are mismatched at a single HLA locus. Transplants from single antigen mismatched siblings in the graft-versus-host direction are associated with a higher risk of graft-versus-host disease (GVHD), although overall survival may not be different from that observed with fully matched siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Transplants from single antigen mismatched siblings in the host-versus-graft direction are associated with higher graft failure and lower survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known how single antigen mismatched sibling donors compare with fully matched unrelated donors. A retrospective study from the Japanese Hematopoietic Cell Transplant Registry compared outcomes among 327 patients who received a serologically defined single antigen",
"    <span class=\"nowrap\">",
"     5/6",
"    </span>",
"    (HLA-A, B, or DRB) mismatched related donor to those of 327 patients who received an",
"    <span class=\"nowrap\">",
"     8/8",
"    </span>",
"    (HLA-A, B, C, DR) allele matched unrelated donor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/27\">",
"     27",
"    </a>",
"    ]. Transplantation with a single antigen mismatched related donor was associated with lower survival at two years (44 versus 59 percent; hazard ratio 1.49; CI 1.19-1.86). Therefore, in those unusual situations where there is a single antigen mismatched related donor, attempting to find a fully matched unrelated donor may be preferred.",
"   </p>",
"   <p>",
"    The use of one antigen mismatched siblings in the graft-versus-host direction is considered in some centers, depending upon the clinical situation (eg, high- versus standard-risk patient, amount of time available for a matched unrelated donor search), with results that are generally similar to those obtained using fully matched siblings or fully matched unrelated donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Haploidentical donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haploidentical related hematopoietic cell donors are those that are mismatched at three of the six loci (HLA-A, -B and &ndash;DR). Although encouraging data have been obtained, this approach is only being explored at centers with expertise in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. Ongoing studies are evaluating novel approaches to induce graft-versus-tumor (GVT) activity and decrease graft-versus-host disease (GVHD) in recipients of haploidentical grafts.",
"   </p>",
"   <p>",
"    Initial studies of haploidentical donors demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an international case series, 80 patients with high-risk hematologic malignancy underwent myeloablative (80 percent) or reduced intensity conditioning followed by haploidentical, unmanipulated, peripheral blood progenitor cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/34\">",
"       34",
"      </a>",
"      ]. GVHD prophylaxis was intensive and included antithymocyte globulin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and the anti-CD25 monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      . Trilineage engraftment was achieved in 91 percent with a median time to engraftment of neutrophils and platelets of 21 and 28 days, respectively. The cumulative incidence of grade II to IV acute GVHD at 100 days was 24 percent (5 percent grade III to IV). The cumulative incidence of extensive chronic GVHD at two years was 6 percent. After a median follow-up of 18 months, the estimated overall survival at three years was 45 percent.",
"     </li>",
"     <li>",
"      In one series of 72 patients undergoing haploidentical transplant, engraftment at 30 days occurred in 88 percent, grade II to IV acute GVHD in 16 percent, and severe chronic GVHD in 8 percent of evaluable patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/31\">",
"       31",
"      </a>",
"      ]. Disease status at the time of transplant was the only factor significantly predictive of outcome. The authors concluded that, in patients who will be treated with an allogeneic transplant, progression of the underlying disease can be avoided by using a haploidentical donor.",
"     </li>",
"     <li>",
"      Another study evaluated the efficacy of haploidentical transplantation with T cell depleted stem cells in 43 patients with high-risk acute leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/35\">",
"       35",
"      </a>",
"      ]. Remarkably, full engraftment was achieved in all patients and none of the evaluable patients developed acute or chronic GVHD. Relapse of the underlying disease occurred mainly in patients with acute lymphoblastic leukemia, especially those who were transplanted with advanced disease. Infection was a significant problem that was thought to be due to the slow recovery of T cell immunity.",
"     </li>",
"     <li>",
"      An analysis was presented by these authors of additional patients receiving full haplotype-mismatched HCT using a preparative regimen of total body irradiation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      , and ATG with CD34+ cell immunoselection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/36\">",
"       36",
"      </a>",
"      ]. Primary engraftment occurred in 94 of 101 assessable patients. Acute GVHD occurred in 8 of 100 patients and chronic GVHD in 5 of 70 assessable patients. Event-free survival was 48 and 46 percent, respectively for the 42 AML and 24 ALL patients who received HCT while in remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Novel approaches in haploidentical donors to decrease complications and increase efficacy have attempted to use adoptive immunotherapy, by adding allodepleted donor T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/37\">",
"     37",
"    </a>",
"    ], manipulated anergic donor T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/38\">",
"     38",
"    </a>",
"    ], genetically engineered donor lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/39\">",
"     39",
"    </a>",
"    ], or ex-vivo expanded mesenchymal stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/40\">",
"     40",
"    </a>",
"    ]. These methods are currently investigational, but have contributed to our understanding of GVHD and the GVT effect.",
"   </p>",
"   <p>",
"    As an example, the infusion of donor derived regulatory T cells (Treg) prior to conventional T cells has been shown in animal models to reduce the risk of GVHD yet allow for GVT effects and improve immune reconstitution. Initial results with this approach appear promising as there was a low risk of GVHD and evidence for enhanced immune recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both clinical transplantation studies and mouse modeling, alloreactive NK cells can protect recipients from myeloid (and to a lesser extent lymphoid) leukemia, graft rejection, and GVHD, possibly through destruction of recipient dendritic cells or direct lysis of alloreactive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These observations raise the possibility of selecting donors for NK cell alloreactivity, since, in the haploidentical setting, most patients have a number of possible donors. The GVT effect of haploidentical donor NK cells have been described in some [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Discrepancies between these reports may reflect the different strategies employed during the transplant procedure, such as the use of ATG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link&amp;anchor=H8#H8\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\", section on 'Natural killer cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies have evaluated the use of immunosuppressants in haploidentical transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/49\">",
"     49",
"    </a>",
"    ]. An initial study of post-transplantation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in 67 patients undergoing haploidentical transplantation using a nonmyeloablative conditioning regimen reported acute graft failure in 13 percent and median times to neutrophil and platelet recovery of 15 and 24 days, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/50\">",
"     50",
"    </a>",
"    ]. Acute GVHD occurred in 34 percent (6 percent grade",
"    <span class=\"nowrap\">",
"     3/4).",
"    </span>",
"    Overall survival at two years was 36 percent. The Bone Marrow Transplant Clinical Trials Network (BMT-CTN) has recently completed a multicenter phase II trial with similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/51\">",
"     51",
"    </a>",
"    ]. This approach will be prospectively compared to double umbilical cord blood transplantation in a phase III design by the BMT-CTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Maternal versus paternal antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mismatching of maternal, rather than paternal, antigens seems to be better tolerated in haploidentical transplants, presumably due to exposure to maternal HLA antigens during the prenatal and perinatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. There is evidence that males and nulliparous females are preferred over parous female donors, since the risk of GVHD has been slightly higher in some studies in the latter group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/54\">",
"     54",
"    </a>",
"    ]. This may be due, in part, to pregnancy-associated alloimmune responses against paternal minor H antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This effect was evaluated in a study of 269 subjects receiving one or two antigen-mismatched sibling or parental non-T cell depleted transplants, using data from the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/57\">",
"     57",
"    </a>",
"    ]. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sibling transplants mismatched for paternal antigens had similar rates of transplant-related mortality (TRM) and graft failure, but higher rates of acute GVHD than maternal-mismatched transplants (relative risk (RR): 1.86, 95% CI: 1.15-3.05).",
"     </li>",
"     <li>",
"      In the first four months post-transplant, father-to-child transplants involved significantly more chronic GVHD than mother-to-child transplants (RR: 2.44, 95% CI: 1.12-5.34).",
"     </li>",
"     <li>",
"      When compared with maternal-mismatched sibling transplants, a transplant from either parent was equally likely to be associated with an increase in treatment-related mortality (RR: 2 for each).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective analysis of 118 consecutive patients with acute leukemia evaluated the effect of sex of the parent on subsequent survival following T cell depleted haploidentical transplantation from a parent. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a control group of leukemic patients receiving transplants from a haploidentical",
"      <strong>",
"       sibling",
"      </strong>",
"      , donor sex had no effect on post-transplant outcome.",
"     </li>",
"     <li>",
"      For patients receiving transplants from a haploidentical",
"      <strong>",
"       parent",
"      </strong>",
"      , five-year event-free survival was significantly better in those who received transplants from the mother, rather than the father (51 versus 11 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The protective effect of a maternal haploidentical donor was seen in both male and female recipients, suggesting that maternal exposure to the child's alloantigens inherited from the father may have influenced these outcomes. Further studies are needed to clarify these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Multiple potential donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;One potential advantage of using haploidentical donors is that within a given family there are usually multiple individuals who could serve as potential donors including parents, siblings, and children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/59\">",
"     59",
"    </a>",
"    ]. As a result, the donor used could be chosen depending upon HLA type, CMV status, blood type, or other features that could have potential clinical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Another advantage is equal availability of donors for all ethnic and racial groups, in contrast to matched unrelated donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     CMV status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sibling donors must be in generally good health, as discussed above, and be serologically negative for viral infection, especially HIV. In the unusual situation in which there is more than one sibling donor, CMV status is usually used to decide which donor to utilize especially if the recipient is CMV seronegative. In this setting, a CMV seronegative donor is preferred since this will greatly reduce the risk of subsequent infection with CMV, assuming that the patient receives CMV seronegative blood products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ABO and Rh status",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABO and Rh compatibility are not required between the donor and recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/64\">",
"     64",
"    </a>",
"    ]. Hemolysis, delayed erythropoietic engraftment, and pure red cell aplasia (PRCA) may complicate ABO-incompatible transplantation after either marrow or PBPC transplantation. However, these complications are not common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/65-70\">",
"     65-70",
"    </a>",
"    ], and may be minimized through the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in the conditioning regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/71\">",
"     71",
"    </a>",
"    ]. A meta-analysis of available studies has concluded that there was no adverse association between any ABO mismatching and survival following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-D seldom develops in RhD-mismatched recipients of a myeloablative allogeneic hematopoietic cell transplantation, but may occur following non-myeloablative conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Data from three studies suggest that major ABO-incompatibility is not a barrier to successful non-myeloablative transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/75-77\">",
"     75-77",
"    </a>",
"    ], although transplant-related morbidity and mortality were higher in a fourth study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/78\">",
"     78",
"    </a>",
"    ]. It is not clear whether major or minor ABO mismatches are associated with a higher incidence of GVHD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If major mismatches are present, additional manipulation of the hematopoietic cell product, such as depleting the product of red cells or plasma prior to infusion, may or may not be required [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/65,82,83\">",
"     65,82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some groups have reported a high incidence of severe immune hemolysis and transplant-related mortality in patients receiving ABO mismatched grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/78\">",
"     78",
"    </a>",
"    ]. To overcome this issue, prophylactic exchange using group O red blood cells was performed in a group of 20 patients receiving non-myeloablative conditioning who demonstrated a minor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bidirectional ABO mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/84\">",
"     84",
"    </a>",
"    ]. Only one patient developed mild hemolysis. When compared with their historical experience, those receiving red cell exchange had improved outcomes.",
"   </p>",
"   <p>",
"    Cases of delayed hemolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PRCA have been described in patients with pre-existing alloantibodies against Rh or ABO antigens, despite the presence of 100 percent donor chimerism of the circulating lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. This phenomenon, including persistence of other host-derived antibodies post-transplantation (eg, anti-platelet alloantibodies), may be due to the presence of long-lived antibody-producing recipient plasma cells surviving the transplantation regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link&amp;anchor=H876308#H876308\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\", section on 'Red blood cell transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MATCHED UNRELATED DONORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1986, the National Marrow Donor Program (NMDP) was established as a repository for HLA-typing information so that unrelated donors and recipients could be matched [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/89\">",
"     89",
"    </a>",
"    ]. Many international registries have also formed which allow for the worldwide search for appropriate donors for those in need of a bone marrow transplant procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, there are over 10 million donors registered in the NMDP data bank and millions others who can be accessed through other donor registries. These potential donors have undergone HLA-A and -B serologic typing. The number of potential donors is increasing with greater public awareness of the need. A significant percentage has also undergone molecular typing.",
"   </p>",
"   <p>",
"    It is more difficult to find a donor for patients from certain ethnic and racial backgrounds. As an example, it has been estimated that a matched unrelated graft has been made available for 50 percent of Caucasians compared with less than 10 percent of minorities in need in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/31\">",
"     31",
"    </a>",
"    ]. This is part due to underrepresentation in the data bank; in addition, African-Americans and Asian-Americans are more polymorphic than Caucasians with respect to HLA and have a relatively large number of haplotypes that are specific to their racial groups, making it more difficult to find donors at any registry size [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6783633\">",
"    <span class=\"h2\">",
"     HLA gene haplotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matching donor and recipient for human leukocyte antigen (HLA) class I (-A, -B, and &ndash;C) and class II (-DRB1 and &ndash;DQB1) haplotypes is a key part of successful allogeneic HCT. Among patients undergoing unrelated donor bone marrow or mobilized peripheral blood progenitor cell HCT, there is a progressive decrease in post-HCT survival with each HLA allele mismatch. Each HLA mismatch may reduce the probability of overall survival at five years by approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. In addition, HLA mismatching is associated with higher rates of graft-versus-host disease (GVHD) in patients transplanted for malignant disorders and higher rates of graft failure in patients transplanted for nonmalignant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. Molecular typing of 10 HLA alleles is preferred by most centers and acceptable donors are generally limited to no more than a single HLA mismatch. In contrast, the impact of the HLA-DP haplotype (a class II HLA) depends upon the specific haplotypes and the direction of the mismatch. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following definitions apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 10 of 10 HLA match refers to donor-recipient pairs matched for HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 at the allele level.",
"     </li>",
"     <li>",
"      A 9 of 10 HLA match refers to pairs with a single allele or antigen mismatch at either HLA-A, HLA-B, HLA-C, HLA-DRB1, or HLA-DQB1.",
"     </li>",
"     <li>",
"      An 8 of 8 HLA match refers to donor-recipient pairs matched for HLA-A, HLA-B, HLA-C, and HLA-DRB1 at the allele level.",
"     </li>",
"     <li>",
"      A 7 of 8 HLA match refers to pairs with a single allele or antigen mismatch at either HLA-A, HLA-B, HLA-C, or HLA-DRB1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antigen mismatches can be further characterized as being in the &ldquo;graft-versus-host&rdquo; direction or the &ldquo;host-versus-graft&rdquo; direction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A graft-versus-host direction mismatch means that the patient possesses one or more alleles not present in the donor. In such a mismatch, the donor T cells from the graft would be expected to mount an alloreactive response towards the patient (host) tissue.",
"     </li>",
"     <li>",
"      A host-versus-graft direction mismatch means that the donor possesses one or more alleles not present in the patient. In such a mismatch, the patient&rsquo;s T cells (host T cells) would be expected to mount an alloreactive response towards the donor (graft) cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A HLA-DP mismatch refers to either a single or a double HLA-DPB1 allele mismatch in the graft-versus-host or host-versus graft direction, or both. HLA-DP mismatches can be further divided into permissive or non-permissive mismatches depending upon the haplotypes involved and the direction of the mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6783558\">",
"     'HLA-DP haplotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Serologic versus molecular HLA typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the donor and recipient are not related, serologic typing alone does not ensure that those individuals share the same HLA genes. This is evident clinically by the higher risk of GVHD in recipients of unrelated donor grafts in earlier studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/101\">",
"     101",
"    </a>",
"    ]. DNA-based techniques are now in routine use, permitting molecular typing, which has demonstrated that only about 55 percent of serologically identical donor and recipient pairs (ie, antigen matched) are highly matched by molecular typing (ie, allele matched) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/96,97,102-104\">",
"     96,97,102-104",
"    </a>",
"    ]. Patients who are truly highly matched appear to have better outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 44 unrelated patient-donor pairs who were serologically matched, the 24 patients who were highly matched by molecular techniques had a 21 percent incidence of severe GVHD compared with 47 percent in those who were not highly matched [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/96\">",
"       96",
"      </a>",
"      ]. Other significant advantages in the highly matched patients were a lower transplant-related mortality (21 versus 57 percent) and a higher three-year actuarial survival (61 versus 13 percent).",
"     </li>",
"     <li>",
"      In a second report, molecular DNA typing was performed in 440 recipients transplanted from unrelated donors who were serologically identical with their donors for HLA-A, B, and DR antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/97\">",
"       97",
"      </a>",
"      ]. When DNA-based genotyping was performed, only 55 percent were identical at the tested HLA-A, B, and DR alleles and 69 percent were identical at the HLA-C alleles which were not tested serologically. HLA-DP matching was present in less than 50 percent but did not appear to affect the outcome. Multivariate analysis showed that mismatching at the HLA-A allele was an independent risk factor for severe GVHD and death (",
"      <a class=\"graphic graphic_figure graphicRef82135 \" href=\"UTD.htm?13/47/14078\">",
"       figure 2",
"      </a>",
"      ), and that mismatching at the HLA-C allele was an independent risk factor for severe GVHD and for a lower rate of recurrence of leukemia in those transplanted for that disease (",
"      <a class=\"graphic graphic_figure graphicRef54913 \" href=\"UTD.htm?9/32/9741\">",
"       figure 3",
"      </a>",
"      ). The importance of class C mismatching has been noted in another series in which patients who had an HLA-C disparity had a relative risk for graft failure of 4.0 after accounting for the contribution HLA-A and HLA-B mismatches [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2004 study of NMDP data from 1874 donor-recipient pairs retrospectively typed at both low and high resolution, mismatches at HLA-A, -B, -C, and -DR1 each had similar adverse effects on mortality, while only HLA-A mismatches demonstrated significant effects on GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/98\">",
"       98",
"      </a>",
"      ]. Adverse effects on outcome were more evident in transplants with low-resolution (ie, antigenic) versus only high-resolution (ie, allelic or molecular) mismatches. Of importance, mismatching at the HLA-DQ or -DP loci did not significantly affect outcome.",
"     </li>",
"     <li>",
"      A larger 2007 study of NMDP data from 3857 donor-recipient pairs concluded that high-resolution matching for HLA-A, -B, -C, and -DRB1 (ie, an",
"      <span class=\"nowrap\">",
"       8/8",
"      </span>",
"      match) was the minimum level of matching associated with the highest survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/94,105\">",
"       94,105",
"      </a>",
"      ]. A single mismatch detected either by low- or high-resolution DNA testing at one of these four loci (ie, a",
"      <span class=\"nowrap\">",
"       7/8",
"      </span>",
"      match) was associated with higher mortality (relative risk 1.25; 95% CI 1.13-1.38). Single mismatches at HLA-B or HLA-C appeared to be better tolerated than mismatches at HLA-A or HLA-DRB1, while mismatches at HLA-DP or HLA-DQ loci and donor factors other than HLA type were not associated with reduced survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most transplant centers now prefer complete molecular matching and will accept a single mismatch to use that donor for a given transplant procedure. However, as noted above, the degree of HLA disparity that is tolerable depends upon many factors, including the clinical situation of the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of these various advances has resulted in continued improvement in the outcome of patients transplanted from unrelated donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/107,108\">",
"     107,108",
"    </a>",
"    ], such that, at the present time, results are very similar to those achieved with matched sibling donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/109\">",
"     109",
"    </a>",
"    ]. As an example, a retrospective study from the CIBMTR evaluated the outcomes of patients with acute myeloid leukemia who underwent a matched related donor (624 patients),",
"    <span class=\"nowrap\">",
"     8/8",
"    </span>",
"    HLA locus matched unrelated donor (1193 patients), or",
"    <span class=\"nowrap\">",
"     7/8",
"    </span>",
"    HLA locus matched unrelated donor (406 patients) HCT between 2002 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/109\">",
"     109",
"    </a>",
"    ]. Recipients of a matched related graft had a lower 100-day cumulative incidence of acute GVHD (33 versus 51 and 53 percent). When compared with recipients of a matched related donor graft, recipients of an",
"    <span class=\"nowrap\">",
"     8/8",
"    </span>",
"    matched unrelated donor graft had similar survival rates at one (42 versus 55 percent) and three (37 versus 39 percent) years post-HCT. When compared with the other two groups, recipients of a",
"    <span class=\"nowrap\">",
"     7/8",
"    </span>",
"    matched unrelated donor graft had a lower rate of overall survival at one year (45 percent), but similar rate of survival at three years (34 percent).",
"   </p>",
"   <p>",
"    Reducing the degree of mismatch with sophisticated genotyping has, as noted above, resulted in decreased mortality following unrelated bone marrow transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/96,97,110\">",
"     96,97,110",
"    </a>",
"    ]. However, requiring more specific testing will undoubtedly reduce the number of donors available for an individual patient and may increase the amount of time required to locate a match, since the vast majority of patients in the registries have been typed with serologic assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6783558\">",
"    <span class=\"h3\">",
"     HLA-DP haplotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies of unrelated donor HCT did not consider the class II HLA-DPB1 haplotype in the selection of donors. Retrospective analyses looking at the impact of HLA-DP haplotype on HCT outcomes suggested that mismatching at the HLA-DP loci was not associated with reduced survival, but was associated with an increased risk of acute GVHD and a reduced risk of disease relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/94,111\">",
"     94,111",
"    </a>",
"    ]. However, subsequent studies suggested that the impact of an HLA-DP mismatch varies depending upon the specific haplotypes and the direction of the mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an international retrospective analysis of 8539 unrelated donor and recipient pairs matched for 10 of 10 HLA alleles (64 percent) or 9 of 10 HLA alleles (36 percent), HLA-DPB1 status was identified as matched (20 percent), non-permissive mismatched (31 percent), or permissive mismatched (49 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/114\">",
"     114",
"    </a>",
"    ]. The effect of HLA-DPB1 status on clinical outcomes was dependent upon the degree of HLA mismatch and type of HLA-DPB1 mismatch:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among pairs with a 10 of 10 HLA match, when compared with permissive mismatches, non-permissive mismatches were associated with a significantly increased risk of overall mortality (hazard ratio [HR] 1.15, 95% CI 1.05-1.25), non-relapse mortality (HR 1.28, 1.14-1.42), and severe acute GVHD (odds ratio [OR] 1.31, 95% CI 1.11-1.54), but not relapse (HR 0.89, 95% CI 0.77-1.02).",
"     </li>",
"     <li>",
"      Also among pairs with a 10 of 10 HLA match, when compared with HLA-DPB1 matches, permissive mismatches were associated with inferior rates of non-relapse mortality (HR 0.86, 95% CI 0.75-0.98) and relapse (HR 1.34, 95% CI 1.17-1.54), but similar overall mortality (HR 0.96, 95% CI 0.87-1.06) and acute GVHD (OR 0.84, 95% CI 0.69-1.03).",
"     </li>",
"     <li>",
"      Among pairs with a 9 of 10 HLA match, when compared with permissive matches, non-permissive mismatches increased the risk of overall mortality (HR 1.10, 95% CI 1.00-1.22), non-relapse mortality (HR 1.19, 1.05-1.36), and severe acute GVHD (OR 1.37, 95% CI 1.13-1.66), but a similar risk of relapse (HR 0.93, 95% CI 0.78-1.11).",
"     </li>",
"     <li>",
"      The clinical outcomes among pairs with a 10 of 10 HLA match with non-permissive HLA-DPB1 mismatches was similar to those with a 9 of 10 HLA match with permissive HLA-DPB1 mismatches or HLA-DPB1 matches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this study suggests that the best clinical outcomes are seen among pairs with a 12 of 12 HLA match (HLA-A, B, C, DRB1, DQB1, DPB1), this level of match will be seen in only approximately 20 percent of patients previously identified as a 10 of 10 HLA match (HLA-A, B, C, DRB1, DQB1). Further delineation of HLA-DPB1 mismatches as permissive and non-permissive allows for more informed donor selection. When all other factors are equal, selection of a 12 of 12 matched donor should be preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21756795\">",
"    <span class=\"h2\">",
"     KIR gene haplotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, matched unrelated donors are identified using HLA-A and HLA-B serologic typing. The impact of matching for non-HLA sites is not as well studied. The killer-cell immunoglobulin-like receptor (KIR) gene encodes natural killer cell immunoglobulin-like receptors that recognize epitopes of HLA-A, HLA-B, and HLA-C, which are also called KIR ligands. KIR haplotypes can be donor activating or donor inhibitory and generally come in one of two broad categories; KIR-haplotype A mainly encode inhibitory receptors and only one activating receptor, while KIR-haplotype B encode more activating receptors (eg, KIR2DS1, KIR3DS1). Initial reports suggest that the donor&rsquo;s KIR gene haplotype may influence transplant outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/42,115-117\">",
"     42,115-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 1409 unrelated transplant donors providing grafts for patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) reported that KIR ligand status affected the outcomes of patients with AML, but not those of patients with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/115\">",
"     115",
"    </a>",
"    ]. Patients with AML who received grafts from donors with B motifs had a lower rate of relapse and superior survival rates. When compared with those of homozygous",
"    <span class=\"nowrap\">",
"     A/A",
"    </span>",
"    donors, grafts from homozygous",
"    <span class=\"nowrap\">",
"     B/B",
"    </span>",
"    donors resulted in a lower cumulative incidence of relapse (15 versus 36 percent). &nbsp;",
"   </p>",
"   <p>",
"    In another study of 1277 patients with AML who underwent unrelated 10 of 10 HLA match or 9 of 10 HLA single mismatch allogeneic transplant, the impact of KIR haplotype on outcomes was at least partially related to the HLA-C haplotype of the donor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/117\">",
"     117",
"    </a>",
"    ]. The rate of relapse was lower among patients whose donor had the KIR2DS1 haplotype (27 versus 33 percent). This benefit from the KIR2DS1 haplotype was primarily seen in transplants from donors who were homozygous or heterozygous for HLA-C1 antigens. In contrast, donor KIR3DS1 positivity did not impact AML relapse rates, but was associated with decreased mortality following transplant (60 versus 67 percent).",
"   </p>",
"   <p>",
"    The KIR gene haplotype is readily available and can easily be performed along with HLA genotyping. When there are multiple HLA-matched potential unrelated donors for a patient with AML, analysis of the KIR gene haplotype may provide guidance in selecting the best match.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Umbilical cord blood donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively high numbers of hematopoietic stem cells are present in umbilical cord blood (UCB) collected at the time of delivery. These cells can be processed and cryopreserved in cord blood banks. Units can be searched similar to the way that unrelated donors are identified. Following HLA-matching to a recipient, the cord blood unit can be transported to the transplant center with minimal delay and used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unrelated UCB offers many practical advantages over unrelated donor bone marrow or mobilized peripheral blood progenitor cells as a source of hematopoietic stem cells including an expanded donor pool, ease of procurement and lack of donor attrition, and decreased graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link&amp;anchor=H61604479#H61604479\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Advantages and limitations of cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations to UCB include an increased risk of graft failure, delayed immune reconstitution, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link\">",
"     \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Initiating the search",
"    </span>",
"    &nbsp;&mdash;&nbsp;To initiate a preliminary search of the National Marrow Donor Program (NMDP), contact the NMDP Office of Patient Advocacy at the following toll-free telephone number: 1-888-999-6743. Alternatively, a preliminary search request form can be submitted through the NMDP website at",
"    <a class=\"external\" href=\"file://www.marrow.org/\">",
"     www.marrow.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Time is an issue, as it may take up to three to six months to complete a search for a matched unrelated donor. This is largely due to the lack of complete typing data for the entire donor population and the large expense required to perform all of the typing tests on all possible donors. In one study of 240 patients of Dutch origin, for example, an appropriate donor could be identified in approximately 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/119\">",
"     119",
"    </a>",
"    ]. The search required six months. Approximately one-third of patients were transplanted, one-third had a potential donor but did not receive the transplant, and one-third did not have a suitable donor.",
"   </p>",
"   <p>",
"    The long search times make this approach feasible only for those diseases with suitable clinical courses. This includes chronic myeloid leukemia (CML), myelodysplastic syndromes, and aplastic anemia, and when searches are initiated early in the course of treatment of patients with high-risk leukemias. Therefore, early discussion and initiation of an unrelated donor search",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral to the transplant center are essential for those patients in whom transplantation is a likely treatment option.",
"   </p>",
"   <p>",
"    One aid in searching for an appropriate donor is the HapLogic program developed by the National Marrow Donor Program. This is a matching algorithm in which the probability of matching at HLA-A, B, C, DRB1 and DQB1 is calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/120\">",
"     120",
"    </a>",
"    ]. The sorting order is for HLA-A, B and DRB1. These probabilities allow the physician to decide whether further testing of possible donors is warranted. If the probability of matching is high, then further testing of donors would be useful, but if the probability is zero or low, alternative donors should be pursued.",
"   </p>",
"   <p>",
"    Once an appropriate donor is identified, the donor must be screened as discussed above for general health and suitability. The bone marrow is harvested locally and then transported to the transplant center. It is feasible to collect donor hematopoietic cells virtually anywhere in the world. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General considerations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     AUTOLOGOUS HCT AFTER A FAILED ALLOGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic stem cells harvested as back-up prior to allogeneic HCT may be potentially useful in the treatment of graft failure or severe GVHD, although the indications for obtaining such back-up stem cells are unclear.",
"   </p>",
"   <p>",
"    The general policies and indications for autologous back-up harvest among the European Group for Blood and Marrow Transplantation centers between 1998 and 2002 were evaluated retrospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/38/26218/abstract/121\">",
"     121",
"    </a>",
"    ]. Thirty-five patients with either graft failure (25), GVHD (8), or relapse (2) retransplanted with autologous back-up cells were reported. Within 100 days after autologous HCT, 21 patients (60 percent) died from treatment-related complications, with estimated one-year overall survivals of 13 and 16 percent for those treated for graft failure or GVHD, respectively.",
"   </p>",
"   <p>",
"    It was concluded that the indications for autologous back-up harvests prior to allogeneic HCT are seriously limited and that such harvests cannot be recommended unless employed in well-designed, selected prospective studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are multiple options available in selecting a donor and stem cell source for an allogeneic hematopoietic cell transplantation (HCT). The clinical problem, overall health of the donor and recipient, infectious history, clinical approach of the transplant center, and other factors are important in deciding what type of donor is selected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"       \"Sources of hematopoietic stem cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most transplant centers prefer an identical twin donor in those rare instances when one is available or an HLA-matched sibling donor if available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Identical twin donors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Matched related donors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an HLA-matched sibling donor is not available, searching the bone marrow registry for unrelated matched donor or umbilical cord blood donor is the next most suitable option. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Matched unrelated donors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Umbilical cord blood donors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice between available donors is also dependent upon the particular expertise and focus of the individual transplant center. The role of haploidentical related donors is under ongoing clinical investigation and is particularly attractive in settings where there is no matched related donor and not time to search for an unrelated donor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Haploidentical donors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/1\">",
"      Hough R, Cooper N, Veys P. Allogeneic haemopoietic stem cell transplantation in children: what alternative donor should we choose when no matched sibling is available? Br J Haematol 2009; 147:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/2\">",
"      Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. JAMA 2010; 303:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/3\">",
"      Rowley SD, Donaldson G, Lilleby K, et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/4\">",
"      Sacchi N, Costeas P, Hartwell L, et al. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/5\">",
"      Lau GK, Lie AK, Kwong YL, et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000; 96:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/6\">",
"      Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 1999; 93:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/7\">",
"      Niederwieser D, Gentilini C, Hegenbart U, et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant 2004; 34:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/8\">",
"      Glasser L, Meloni-Ehrig A, Greaves W, et al. Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation. Transfusion 2009; 49:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/9\">",
"      Kiss TL, Chang H, Daly A, et al. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals. Bone Marrow Transplant 2004; 33:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/10\">",
"      Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/11\">",
"      Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000; 96:4096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/12\">",
"      Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/13\">",
"      Schultz KR, Green GJ, Wensley D, et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994; 84:3212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/14\">",
"      Rotta M, Storer BE, Storb RF, et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010; 115:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/15\">",
"      Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007; 110:4588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/16\">",
"      Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008; 111:3901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/17\">",
"      Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/18\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/19\">",
"      Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21:3744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/20\">",
"      Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/21\">",
"      Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood 2003; 102:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/22\">",
"      Broadfield ZJ, Hain RD, Harrison CJ, et al. Complex chromosomal abnormalities in utero, 5 years before leukaemia. Br J Haematol 2004; 126:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/23\">",
"      Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/24\">",
"      Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003; 102:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/25\">",
"      Teshima T, Matsuo K, Matsue K, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 2005; 130:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/26\">",
"      Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/27\">",
"      Kanda J, Saji H, Fukuda T, et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood 2012; 119:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/28\">",
"      Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15:4777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/29\">",
"      Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118:6006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/30\">",
"      Aversa F, Terenzi A, Tabilio A, et al. Addition of PBPCs to the marrow inoculum allows engraftment of mismatched T cell-depleted transplants for acute leukemia. Bone Marrow Transplant 1996; 17 Suppl 2:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/31\">",
"      Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89:3864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/32\">",
"      Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/33\">",
"      Guo M, Hu KX, Liu GX, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol 2012; 30:4084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/34\">",
"      Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/35\">",
"      Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/36\">",
"      Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/37\">",
"      Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/38\">",
"      Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/39\">",
"      Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/40\">",
"      Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110:2764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/41\">",
"      Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/42\">",
"      Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/43\">",
"      Olson JA, Leveson-Gower DB, Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010; 115:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/44\">",
"      Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/45\">",
"      Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/46\">",
"      Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100:3825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/47\">",
"      Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/48\">",
"      Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/49\">",
"      Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/50\">",
"      Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/51\">",
"      Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/52\">",
"      Ichinohe T, Uchiyama T, Shimazaki C, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 2004; 104:3821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/53\">",
"      Aoyama K, Koyama M, Matsuoka K, et al. Improved outcome of allogeneic bone marrow transplantation due to breastfeeding-induced tolerance to maternal antigens. Blood 2009; 113:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/54\">",
"      Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/55\">",
"      Verdijk RM, Kloosterman A, Pool J, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 2004; 103:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/56\">",
"      van Halteren AG, Jankowska-Gan E, Joosten A, et al. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood 2009; 114:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/57\">",
"      van Rood JJ, Loberiza FR Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/58\">",
"      Stern M, Ruggeri L, Mancusi A, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/59\">",
"      Veys P, Amrolia P, Rao K. The role of haploidentical stem cell transplantation in the management of children with haematological disorders. Br J Haematol 2003; 123:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/60\">",
"      Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100:3908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/61\">",
"      Grumet FC, Hiraki DD, Zehnder JL, et al. CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant 2001; 7:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/62\">",
"      Shimazaki C, Ochiai N, Uchida R, et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood 2003; 101:3334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/63\">",
"      Keen LJ, DeFor TE, Bidwell JL, et al. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 2004; 103:3599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/64\">",
"      Wirk B, Klumpp TR, Ulicny J, et al. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation. Transfusion 2008; 48:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/65\">",
"      Rowley SD, Liang PS, Ulz L. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components. Bone Marrow Transplant 2000; 26:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/66\">",
"      Bolan CD, Childs RW, Procter JL, et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001; 112:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/67\">",
"      Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001; 98:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/68\">",
"      Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000; 40:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/69\">",
"      Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/70\">",
"      Mielcarek M, Zaucha JM, Sandmaier B, et al. Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility. Br J Haematol 2002; 116:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/71\">",
"      Mijovic A, Abdallah A, Pearce L, et al. Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens. Br J Haematol 2008; 142:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/72\">",
"      Kanda J, Ichinohe T, Matsuo K, et al. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion 2009; 49:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/73\">",
"      Mijovic A. Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transplants with non-myeloablative conditioning. Vox Sang 2002; 83:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/74\">",
"      Cid J, Lozano M, Fern&aacute;ndez-Avil&eacute;s F, et al. Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases. Transfusion 2006; 46:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/75\">",
"      Maciej Zaucha J, Mielcarek M, Takatu A, et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol 2002; 119:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/76\">",
"      Canals C, Mu&ntilde;iz-D&iacute;az E, Mart&iacute;nez C, et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion 2004; 44:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/77\">",
"      Wang Z, Sorror ML, Leisenring W, et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. Br J Haematol 2010; 149:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/78\">",
"      Worel N, Kalhs P, Keil F, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 2003; 43:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/79\">",
"      Stussi G, Seebach L, Muntwyler J, et al. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. Br J Haematol 2001; 113:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/80\">",
"      Worel N, Greinix HT, Keil F, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002; 42:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/81\">",
"      Erker CG, Steins MB, Fischer RJ, et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005; 45:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/82\">",
"      Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/83\">",
"      Daniel-Johnson J, Schwartz J. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation? Transfusion 2011; 51:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/84\">",
"      Worel N, Greinix HT, Supper V, et al. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion 2007; 47:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/85\">",
"      Izumi N, Fuse I, Furukawa T, et al. Long-term production of pre-existing alloantibodies to E and c after allogenic BMT in a patient with aplastic anemia resulting in delayed hemolytic anemia. Transfusion 2003; 43:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/86\">",
"      Griffith LM, McCoy JP Jr, Bolan CD, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/87\">",
"      van Tol MJ, Gerritsen EJ, de Lange GG, et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 1996; 87:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/88\">",
"      Ang HA, Apperley JF, Ward KN. Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity. Blood 1997; 89:4646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/89\">",
"      Stroncek D, Bartsch G, Perkins HA, et al. The National Marrow Donor Program. Transfusion 1993; 33:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/90\">",
"      Oudshoorn M, van Leeuwen A, vd Zanden HG, van Rood JJ. Bone Marrow Donors Worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/91\">",
"      Gratwohl A, Baldomero H, Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/92\">",
"      Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995; 60:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/93\">",
"      Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/94\">",
"      Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/95\">",
"      Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 2007; 13:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/96\">",
"      Speiser DE, Tiercy JM, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87:4455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/97\">",
"      Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/98\">",
"      Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/99\">",
"      Horan J, Wang T, Haagenson M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood 2012; 120:2918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/100\">",
"      Zino E, Frumento G, Marktel S, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 2004; 103:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/101\">",
"      Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/102\">",
"      Prasad VK, Kernan NA, Heller G, et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999; 93:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/103\">",
"      Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/104\">",
"      Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/105\">",
"      Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2010; 150:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/106\">",
"      Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 2004; 104:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/107\">",
"      Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/108\">",
"      Finke J, Schmoor C, Lang H, et al. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003; 21:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/109\">",
"      Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012; 119:3908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/110\">",
"      Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24:5695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/111\">",
"      Shaw BE, Gooley TA, Malkki M, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007; 110:4560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/112\">",
"      Crocchiolo R, Zino E, Vago L, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009; 114:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/113\">",
"      Ciurea SO, Thall PF, Wang X, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118:5957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/114\">",
"      Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 2012; 13:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/115\">",
"      Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/116\">",
"      Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/117\">",
"      Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/118\">",
"      Karanes C, Confer D, Walker T, et al. Unrelated donor stem cell transplantation: the role of the National Marrow Donor Program. Oncology (Williston Park) 2003; 17:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/119\">",
"      Oudshoorn M, Cornelissen JJ, Fibbe WE, et al. Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients. Bone Marrow Transplant 1997; 20:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/120\">",
"      Hurley CK, Wagner JE, Setterholm MI, Confer DL. Advances in HLA: practical implications for selecting adult donors and cord blood units. Biol Blood Marrow Transplant 2006; 12:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/38/26218/abstract/121\">",
"      Stelljes M, van Biezen A, Slavin S, et al. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2008; 42:739.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3535 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26218=[""].join("\n");
var outline_f25_38_26218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effect of donor age and other characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10032308\">",
"      Donor use of statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IDENTICAL TWIN DONORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MATCHED RELATED DONORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MISMATCHED RELATED DONORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10032398\">",
"      Single antigen mismatched siblings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Haploidentical donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Maternal versus paternal antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Multiple potential donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CMV status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ABO and Rh status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MATCHED UNRELATED DONORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6783633\">",
"      HLA gene haplotypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Serologic versus molecular HLA typing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6783558\">",
"      - HLA-DP haplotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21756795\">",
"      KIR gene haplotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Umbilical cord blood donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Initiating the search",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AUTOLOGOUS HCT AFTER A FAILED ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3535|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/10/43169\" title=\"figure 1\">",
"      Donor selection HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/47/14078\" title=\"figure 2\">",
"      HLA A and survival post HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/32/9741\" title=\"figure 3\">",
"      HLA C relapse leukemia post HCT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=related_link\">",
"      Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_38_26219="WHO mineral mix";
var content_f25_38_26219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of mineral mix solution used in the treatment of malnutrition in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Substance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium chloride",
"       </td>",
"       <td>",
"        89.5 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tripotassium citrate",
"       </td>",
"       <td>",
"        32.4 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium chloride (MgCl",
"        <sub>",
"         2",
"        </sub>",
"        - 6H",
"        <sub>",
"         2",
"        </sub>",
"        O)",
"       </td>",
"       <td>",
"        30.5 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc acetate",
"       </td>",
"       <td>",
"        3.3 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper sulfate",
"       </td>",
"       <td>",
"        0.56 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium selenate*",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium iodide*",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water to make",
"       </td>",
"       <td>",
"        1000 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If it is not possible to weigh very small amounts accurately, this substance may be omitted.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26219=[""].join("\n");
var outline_f25_38_26219=null;
var title_f25_38_26220="Causes of fecal incontinence";
var content_f25_38_26220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of fecal incontinence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Structural abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anal sphincter muscles",
"       </td>",
"       <td>",
"        Obstetrical injury, hemorrhoidectomy, anal dilation, radiation, inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectum",
"       </td>",
"       <td>",
"        Prolapse, hypersensitivity/hyposensitivity, neoplasms, congenital abnormalities, excessive perineal descent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Puborectalis muscle",
"       </td>",
"       <td>",
"        Trauma, obstetrical injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pudendal nerve",
"       </td>",
"       <td>",
"        Surgical injury, excessive perineal descent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system, spinal cord, autonomic nervous system",
"       </td>",
"       <td>",
"        Spinal cord injury, head injury, stroke, back surgery, diabetes mellitus, multiple sclerosis, tabes dorsalis, cauda equina injury or tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Functional abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal sensation",
"       </td>",
"       <td>",
"        Obstetrical injury, central nervous system/autonomic nervous system injury, diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal impaction",
"       </td>",
"       <td>",
"        Dyssynergic defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Stool characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume and consistency",
"       </td>",
"       <td>",
"        Inflammatory bowel disease, irritable bowel syndrome, medications, infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritants",
"       </td>",
"       <td>",
"        Bile salt malabsorption, laxatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hard stools and retention",
"       </td>",
"       <td>",
"        Dyssynergic defecation, fecal impaction, medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical mobility and cognitive function",
"       </td>",
"       <td>",
"        Aging, disability, dementia, sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychosis",
"       </td>",
"       <td>",
"        Willful soiling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications",
"       </td>",
"       <td>",
"        Laxatives, anticholinergics, antidepressants, caffeine, muscle relaxants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food intolerance",
"       </td>",
"       <td>",
"        Lactose, fructose, sorbitol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lazarescu A, Turnbull GK, Vanner S. Investigating and treating fecal incontinence: When and how. Can J Gastroenterol 2009; 23:301. Copyright &copy; 2009 Pulsus Group Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26220=[""].join("\n");
var outline_f25_38_26220=null;
var title_f25_38_26221="Injury prevention resources US";
var content_f25_38_26221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55012%7EPEDS%2F78048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55012%7EPEDS%2F78048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Injury prevention resources (US)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advocates for Highway and Auto Safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        202-408-1711",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.saferoads.org\" target=\"_blank\">",
"         www.saferoads.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Centers for Disease",
"        <span class=\"subtitle2_single\">",
"         Control",
"        </span>",
"        and Prevention Protect the Ones You Love",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cdc.gov/safechild\" target=\"_blank\">",
"         www.cdc.gov/safechild",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Child Welfare League of America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        202-688-4200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cwla.org\" target=\"_blank\">",
"         www.cwla.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children's Safety Network",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.childrenssafetynetwork.org\" target=\"_blank\">",
"         www.childrenssafetynetwork.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Harborview Injury Prevention and Research Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.depts.washington.edu/hiprc\" target=\"_blank\">",
"         www.depts.washington.edu/hiprc",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury Control and Emergency Health Services Section of the American Public Health Association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.apha.org/membergroups/sections/aphasections/icehs\" target=\"_blank\">",
"         www.apha.org/membergroups/sections/aphasections/icehs",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury Prevention Research Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.public-health.uiowa.edu/IPRC\" target=\"_blank\">",
"         www.public-health.uiowa.edu/IPRC",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mothers Against Drunk Driving-MADD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        877-275-6233, 877-ASK-MADD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.madd.org\" target=\"_blank\">",
"         www.madd.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Safe Kids Campaign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        202-662-0600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.safekids.org\" target=\"_blank\">",
"         www.safekids.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Safety Council",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        800-621-7615",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.nsc.org\" target=\"_blank\">",
"         www.nsc.org",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Center for Injury Prevention and Control (NCIPC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        800-232-4636",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cdc.gov/injury/index.html\" target=\"_blank\">",
"         www.cdc.gov/injury/index.html",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        US Consumer Product Safety Commission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        800-638-2772 (hotline), 800-638-CPSC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.cpsc.gov\" target=\"_blank\">",
"         www.cpsc.gov",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mace SE, Gerardi MJ, Dietrich AM, et al. Ann Emerg Med 2001; 38:405.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Injury prevention resources (UK)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Child Accident Prevention Trust",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.capt.org.uk\" target=\"_blank\">",
"         www.capt.org.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Royal Society for the Prevention of Accidents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.rospa.co.uk\" target=\"_blank\">",
"         www.rospa.co.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury Minimization Programme for Schools (IMPS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.impsweb.co.uk\" target=\"_blank\">",
"         www.impsweb.co.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gloucestershire Home Safety Check Scheme and Herefordshire Home Check",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.homesafety.co.uk\" target=\"_blank\">",
"         www.homesafety.co.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Maconochie I. Accident prevention. Arch Dis Child 2003; 88:275.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26221=[""].join("\n");
var outline_f25_38_26221=null;
var title_f25_38_26222="Effect precondition time II";
var content_f25_38_26222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Effect of ischemic preconditioning is related to the time elapsed after the last episode of angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 345px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among patients undergoing balloon angioplasty, the likelihood a having an ischemic response during the second balloon inflation was directly related to the time since the last spontaneous episode of angina. This seemingly paradoxical finding can be explained by the fact that, when the time since the last episode of angina was more than six hours, the patient was more likely to have an ischemic response during the first balloon inflation, thereby providing ischemic preconditioning for the second inflation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lim, RR, Laskey, WK, J Am Coll Cardiol 1997; 30:1461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26222=[""].join("\n");
var outline_f25_38_26222=null;
var title_f25_38_26223="Endothelial dysfunction CHD III";
var content_f25_38_26223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary endothelial dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In comparison to acetylcholine, an infusion of nitroglycerin produces dilation in all segments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles E Rackley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_38_26223=[""].join("\n");
var outline_f25_38_26223=null;
